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Abstract 
The aim of this PhD project was to evaluate alternative procedures for genetic testing 
and counselling of patients newly diagnosed with breast or ovarian cancer, in order to 
meet the expected increasing need of this health service.  
We performed a prospective study, the DNA-BONus study, in which we consecutively 
offered BRCA testing and familial risk assessment to unselected patients with newly 
diagnosed breast (N=893) or ovarian (N=122) cancer between September 2012 and 
February 2015, without formal pre-test genetic counselling. Out of the 488 patients 
who underwent genetic testing 7 of 405 patients (2%) with breast cancer and 19 of 83 
patients (22%) with ovarian cancer carried a germline pathogenic BRCA variant 
(Paper I). All carriers fulfilled at least one of the Norwegian BRCA test criteria 
(Paper I). There was a significant decline in the mean levels of anxiety symptoms 
(Paper I) and cancer related psychological distress (Paper II) from inclusion to six 
months after dissemination of the BRCA test result. Predictors of increased distress 
were young age, short time since diagnosis, low level of perceived social support, high 
level of decisional conflict, diagnosis of ovarian cancer, and living with a partner 
(Paper II). By investigating RNA splicing, we showed that the intronic BRCA1 
c.5407-25T>A variant leads to partial skipping of exon 22, resulting in the truncated 
protein p.Gly1803GlnfsTer11. Combined with allele frequency data and clinical 
information from 20 families, this indicated that BRCA1 c.5407-25T>A is a likely 
pathogenic variant with reduced penetrance (Paper III).  
In conclusion, the current thesis showed that a simplified procedure for BRCA testing 
was accepted and overall well tolerated by women newly diagnosed with breast or 
ovarian cancer. However, we also identified more vulnerable subgroups that may need 
more counselling and support to benefit from diagnostic BRCA testing. Testing of 
large groups of individuals with low a priori risk of carrying a germline BRCA 
pathogenic variant, like unselected patients with breast cancer in our study, may lead 
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1. Introduction 
Cancer constitutes a major health problem and is the second leading cause of death 
globally [1]. While ageing can be considered the main risk factor for cancer 
development, identification of environmental risk factors like radiation, tobacco use, 
and infections has been important to develop strategies for prevention and early 
diagnosis of cancer. However, hereditary factors also play a significant role, and in a 
subset of cancer cases the underlying main cause is a germline pathogenic variant in a 
high-penetrant cancer gene. It is important to identify patients with a hereditary cause 
of cancer because this gives a unique opportunity to prevent cancer, i.e. a second 
primary cancer in the patient, and cancer in relatives who have inherited the same 
predisposition. In addition, genetic information can guide treatment decisions in 
patients already affected by cancer.  
This thesis concerns different aspects connected to BRCA genetic testing of patients 
with breast and/or ovarian cancer. The work presented was carried out between 2012 
and 2019, a period of time in which the demand of genetic testing escalated – both 
inside and outside the healthcare system. In this introduction, the background for the 
study will be presented. 
1.1 Short overview of important developments in medical 
genetics 
Medical genetics is a relatively young discipline within medicine. It builds on a longer 
research tradition of human genetics [2], where some important milestones were 
Gregor Mendel’s first description of the laws of inheritance in 1865, the determination 
of the DNA double-helix structure in 1953 [3, 4], and the identification of the correct 
human chromosome number in 1956 [5]. After cracking of the genetic code in the 
1960’s it became possible to study genetic variation and its association with disease, 
leading to the development of the field of medical genetics from the 1970’es [2]. 
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Already in 1972, clinical genetics was acknowledged as a separate speciality field in 
medicine in Norway, as one of the first countries in the world [6]. 
Victor McKusick (1921-2008), widely considered the founding father of medical 
genetics, started to catalogue human genetic phenotypes in the annual compendium 
“Mendelian Inheritance in Man” (“MIM) in 1966. Due to great advances in molecular 
techniques thousands of genetic conditions have been mapped and characterised and 
are now easily accessible in the online version “Online Mendelian Inheritance in Man” 
OMIM [7]. Sanger sequencing of DNA was introduced in 1975 [8], but it took an 
extensive collaborative effort to sequence the complete human genome – through the 
Human Genome Project initiated in 1990 and completed in 2003 [9, 10]. The 
development of massive parallel sequencing techniques in the following decade, also 
known as next generation sequencing (NGS), increased the capacity and reduced the 
turn-around time of sequencing dramatically [11-13]. While it took 13 years and $2.7 
billion to sequence the first complete human genome, an individual’s genome can now 
be sequenced in a few days for less than $1.500 [14]. 
The combination of rapid development in technologies and plummeting costs has 
made clinical genetic testing increasingly affordable and accessible. Today NGS 
allows for analysis of multiple genes simultaneously at the same cost as single gene 
tests, and diagnostic genetic testing is entering everyday practice in most medical 
disciplines.  
1.2 Breast cancer and ovarian cancer in the population 
Breast cancer is the most common cancer among women, with globally more than 2 
million new cases diagnosed each year [15]. In Norway 3,596 new cases of breast 
cancer were registered in 2018 and the estimated risk of developing breast cancer by 
the age of 75 years is 8.9% [16]. The 5-year relative survival rate is 90.7%, and the 15- 
year relative survival rate is 78.3% [16]. Ovarian cancer is less common; around 
300,000 new cases are diagnosed yearly worldwide (444 new cases in Norway in 
2018), but the survival is poor: 48.9% and 33.0% 5- and 15-year relative survival rate, 
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respectively [15, 16]. The cumulative risk of ovarian cancer by the age of 75 years in 
the population is 1.3% [16]. 
1.3 Cancer and genetics 
At the cellular level, cancer is a genetic disease. The disorder is characterised by 
uncontrolled cell growth caused by genomic instability [17]. The transformation of 
normal cells into cancer cells, i.e. tumourigenesis, is a multistep process in which 
alterations in multiple cancer genes accumulate over time. In most cases, the first of 
these genetic events occurs in a somatic single cell, i.e. it is a somatic mutation, and 
the subsequent genetic alterations occur in daughter cells from this single cell. The 
process often takes several years, and increasing age is the most important risk factor 
for developing cancer. However, in the case of hereditary cancer, the first genetic 
alteration is already present at conception, i.e. it is a germline mutation and will 
therefore be present in all cells of the body. People carrying germline pathogenic 
variants in cancer genes are more prone to develop cancer at a young age and to 
develop multiple primary tumours.  
1.4 Hereditary breast and ovarian cancer 
Although most breast and ovarian cancers occur in patients with no familial risk of the 
disease, there is an important minority of cases that are caused by a germline 
pathogenic variant (Figure 1). The first report of a family with suspected hereditary 
breast and ovarian cancer was published in 1971 [18]. In 1994 the BReast CAncer 1 
gene (BRCA1) was identified [19], followed by the BReast CAncer 2 gene (BRCA2) in 
1995 [20]. After 25 years of search for “BRCA3” it has become evident for most 
researchers that additional single genes contributing to a substantial share of hereditary 
breast and ovarian cancer do not exist [21]. This leaves BRCA1 and BRCA2 – hereafter 
collectively denoted BRCA - the main causative genes for autosomal dominant 
hereditary breast and ovarian cancer. Individuals with a pathogenic variant in one of 
these genes will be referred to as “BRCA carriers” in this thesis. In addition, there are 
other genes associated with high risk of breast cancer, like TP53, PTEN, STK11, 
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PALB2 and CDH1 [22-26], but pathogenic variants in these genes are far less 
prevalent than pathogenic variants in the BRCA genes. In addition, there are genes 
associated with moderate risk of breast cancer, mainly ATM and CHEK2 [27, 28]. 
More than 15% of patients with breast cancer have one or more first degree relatives 
with breast cancer [29]. However, in a substantial share of these familial breast cancer 
cases an underlying genetic alteration in known risk genes cannot be identified. There 
is increasing evidence that a fraction of these cases can be explained by a polygenic 
risk, where multiple common genetic variants together give an elevated risk, while 
each variant alone is only associated with a minor risk [30]. Ovarian cancer can also be 
seen in Lynch syndrome (hereditary colorectal cancer) caused by genetic alterations in 
the mismatch repair (MMR) genes (mainly MLH1, MSH2 and MSH6) [31-33] and in 
rare cases familial ovarian cancer can be caused by alterations in RAD51C, RAD51D 
or BRIP1 [33-38].  
Figure 1 
Relative distribution of different hereditary factors contributing to A) breast cancer [28, 29], 
and B) ovarian cancer [31, 33, 35]   
 
1.4.1 BRCA1 and BRCA2 
BRCA1 is located on chromosome 17q21.3 and consists of 23 coding exons. The main 
transcript (NM_007294.3) encodes a large protein of approximately 220 kDa 
consisting of 1863 amino acids [39]. The BRCA1 protein has been implicated in 
numerous important cellular processes including cell cycle regulation, maintenance of 
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genome integrity, and repair of double stranded DNA breaks through homologous 
recombination [40]. Through the two BRCA1 C-terminal (BRCT) domains, BRCA1 
interacts with proteins involved in transcription and DNA damage response [41]. 
BRCA2 is located on chromosome 13q13.1 and consists of 27 coding exons. The main 
transcript (NM_000059.3) encodes a protein of 384 kDa consisting of 3418 amino 
acids [42]. Like BRCA1, the BRCA2 protein also has a central role in homologous 
DNA repair [41]. 
1.4.2 Prevalence 
The prevalence and relative contribution of germline pathogenic variants in BRCA1 
and BRCA2 varies between different populations. Together these two genes account 
for 1.8-6.1% of patients with breast cancer [43-47] and 8.0-28.5% of patients with 
ovarian cancer [31, 33, 48-51]. 
1.4.3 Cancer risk 
For a woman with a BRCA1 pathogenic variant, the cumulative risk by age 70 years is 
45-66% for developing breast cancer and 31-59% for developing ovarian, fallopian 
tube, or primary peritoneal cancer [52-55]. The corresponding risk for a woman with a 
BRCA2 pathogenic variant is 27-61% for breast cancer and 6-16.5% for ovarian, 
fallopian tube, or primary peritoneal cancer [52-55]. For women already affected by 
breast cancer, the risk of contralateral breast cancer within 20 years is around 40% for 
BRCA1 carriers and 26% for BRCA2 carriers [53].  In addition, pathogenic variants in 
BRCA2 are associated with increased risk of pancreatic cancer in both men and women 
and an aggressive form of prostate cancer in men [56-59]. Men with BRCA2 
pathogenic variants are also at increased risk for breast cancer [60].    
There are some striking features concerning pathology of cancers occurring in BRCA 
carriers. Breast cancer among BRCA1 carriers are more often high grade and triple 
negative, i.e. negative for oestrogen receptor, progesterone receptor and human 
epidermal growth factor receptor 2 (HER2), compared to sporadic breast cancer [61]. 
BRCA2 carriers, however, show distribution of breast cancer subtypes more similar to 
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the general population of breast cancer patients [61]. Ovarian cancer is mainly high 
grade serous in both BRCA1 and BRCA2 carriers [31, 33]. 
1.4.4 Surveillance and risk-reduction 
Women carrying a BRCA pathogenic variant are offered surveillance and risk-reducing 
surgery, to reduce the risk of cancer and/or cancer related mortality [62, 63]. The 
Norwegian guidelines recommend annual breast MRI and mammography from age 25, 
bilateral salpingo-oophorectomy at age 35-40 years (BRCA1) or 40-45 years (BRCA2), 
and optional risk reducing mastectomy from age 25 years [64]. While the intention 
with regular surveillance is early detection and better prognosis of cancer, risk 
reducing surgery aims at reducing the incidence of cancer. Breast screening with MRI 
and mammography has been shown to downstage breast cancer and improve survival 
in BRCA carriers [65, 66]; in contrast, screening for ovarian cancer has been 
documented non-effective [67, 68]. Risk reducing bilateral salpingo-oophorectomy 
reduces the incidence of ovarian cancer and improves survival [69] and risk reducing 
mastectomy has been shown effective to reduce the incidence of breast cancer [70, 
71].  
Chemoprophylaxis with anti-oestrogens is used in some countries [62, 63], but has not 
been part of the recommendations for BRCA carriers in Norway. 
1.4.5 Cancer treatment 
Previously, cancer treatment did not differ depending on BRCA carrier status. Even if 
most surgeons would hesitate to do breast conserving surgery, until recently the 
Norwegian guidelines did not specify breast cancer treatment for BRCA carriers. With 
increasing evidence of the effect of platinum based chemotherapy in BRCA carriers 
[72, 73], however, carboplatin was added to standard neoadjuvant therapy for BRCA 
carriers with local advanced breast cancer in the national treatment guidelines in 
November 2015 [74]. A specific recommendation for primary breast cancer surgery in 
BRCA carriers, i.e. bilateral mastectomy, was included in the 2018 guidelines [75]. 
Targeted treatment with Poly (ADP-ribose) polymerase (PARP)-inhibitors was 
approved by the US Food and Drug Administration (FDA) in 2014 [76] and was 
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subsequently approved in Norway for treatment of ovarian cancer with an identified 
BRCA pathogenic variant (germline or somatic) in 2015 [77]. In addition to having 
documented effect on breast and ovarian cancer, PARP-inhibitors may also be 
effective in other cancer types with BRCA deficiency [78-82].  
Accordingly, the identification of a BRCA pathogenic variant has impact on both the 
treatment of patients affected with BRCA-related cancer as well as upon their healthy 
relatives – who can benefit from increased surveillance and risk-reducing surgery.  
1.5 BRCA genetic testing  
More than ten thousand different germline variants have been found in the BRCA 
genes [83-85]. When interpreting BRCA variants with respect to pathogenicity, a 5-tier 
system is often used [86], in which class 1 variants are benign, class 2 likely benign 
(also called non-disease causing), class 3 variants of uncertain clinical significance 
(VUS), class 4 likely pathogenic and class 5 pathogenic (collectively called disease 
causing). The variant interpretation is based on a number of variables such as allele 
frequencies in the general population, segregation data from the affected families, 
reputable sources like PubMed and ClinVar, and functional assays, building evidence 
of pathogenicity or benign impact, as presented by the ACMG (American College of 
Medical Genetics) guidelines [87] and ENIGMA (Evidence-based Network for the 
Interpretation of Germline Mutant Alleles) criteria [88]. 
BRCA variants classified as likely pathogenic (class 4) and pathogenic (class 5) 
increase the risk of cancer by impairing the protein structure or function. Other 
variants classified as likely benign or benign are not associated with increased risk of 
cancer. However, for a large number of BRCA variants the knowledge is very limited 
or conflicting, and these are therefore classified as VUS (class 3).  
Soon after the identification of the BRCA genes it became evident that in some 
populations, e.g. the Ashkenazi Jewish and the Polish, a limited number of founder 
mutations were causing a majority of the hereditary breast and ovarian cancer cases 
[89]. This was also the case for Norway, where four founder mutations were reported 
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to be responsible for 68% of families with hereditary breast and ovarian cancer [90]. 
Customised founder mutations tests were developed, which made it possible to offer 
genetic testing to a large number of individuals at a relatively low cost.  
The Norwegian BRCA founder mutation test included initially two prevalent 
pathogenic BRCA1 variants, c.1556del (BIC: 1675delA) and c.1016dup (BIC: 
1135insA). It was soon expanded with c.697_698del (BIC: 816delGT) and 
c.3228_3229del (BIC: 3347delAG). Later, other pathogenic variants were added to the 
test, as more frequent pathogenic variants were discovered by Sanger sequencing of 
families with high suspicion of hereditary breast and ovarian cancer. A two-step model 
was commonly used in familial cancer clinics in Norway until 2015: a founder 
mutation test was offered at low threshold to affected and unaffected individuals 
seeking genetic counselling for hereditary breast and ovarian cancer. If the founder 
mutation test was negative, or if the family was not of Norwegian ancestry, more 
comprehensive analyses like Sanger sequencing and Multiplex Ligation Probe 
Amplification (MLPA) of BRCA1 and BRCA2 were performed in affected members of 
families fulfilling the criteria for high suspicion of a pathogenic BRCA variant. These 
criteria have been continuously revised, see Table 1.  
Because genetic tests were expensive, criteria were developed to select patients with 
high likelihood of having a pathogenic BRCA variant. Similar criteria have been used 
in other countries [91]. With falling costs, the criteria were broadened at each revision, 
both for the founder mutation test and for comprehensive analysis with sequencing of 
the total coding region of BRCA1 and BRCA2 (Table 1) [64, 74, 92]. The 2010 criteria 
were the result of a long-standing national debate between leading health professionals 
in several speciality fields (surgeons, gynaecologists, oncologists and clinical 
geneticists), Norwegian health authorities, and other stakeholders [92-94].  
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Table 1 Development in the Norwegian diagnostic BRCA genetic test criteria over 
the years 
Abbreviations: FBC: female breast cancer, BC: breast cancer OC: ovarian cancer; FDR: first degree 
relative (or second degree relative through male); MLPA: multiplex ligation probe amplification. 
*In addition to these criteria, surgeons, oncologists and gynaecologists may order diagnostic BRCA 
testing if the test result will have major impact on treatment decisions. 
 





















  < 50 years < 35 years < 50 years < 60 years 
OC < 45 years  < 70 years < 50 years Any age Any age 
Bilateral 
FBC 
< 60 years < 35 years Any age < 50 years < 60 years  
FBC and OC BC < 60 
years, OC 
any age 
BC < 50 
years, OC     
< 60 years 
Any age BC < 50 
years, OC 
any age 
Any age Any age 
Male BC   Any age Any age Any age Any age 
FBC and a 
FDR with 
BC 
Both BC    
< 50 years 
Both BC < 35 
years 
One of the 
BC < 50 
years 
Mean age 50 
years 
Mean age 55 
years 
Mean age 55 
years 
FBC and a 
FDR with 
OC 
BC < 60 
years, OC 
any age 
BC < 50 
years, OC < 
60 years 
Any age BC < 50 
years, OC 
any age 
Any age Any age 
FBC and ≥ 2 
FDR with 
BC 
≥ 4 BC, any 
age 
≥ 3 BC <50 
years 
Any age BC mean age 
60 years 
Any age Any age 
OC and FDR 
with OC 
Any age Both OC < 60 
years 
Any age Any age   




cancer < 55 
years 
BC any age 
and FDR  
with prostate 
cancer < 55 
years 
BC any age 
and FDR  
with prostate 
cancer < 55 
years 
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The advantage of a test that only detects well-known pathogenic variants that have 
previously been identified in multiple families with hereditary breast and ovarian 
cancer (“founder mutation test”) is that the interpretation of the result is quite 
straightforward. With more comprehensive testing, like sequencing of the total 
coding regions of one or more genes, there is an inherent risk of detecting sequence 
variants of uncertain clinical significance (VUS). The risk of detecting a VUS is 
higher in patients with low a priori risk of carrying a pathogenic variant, and 
increases with the number of genes investigated [95]. According to international 
guidelines, a VUS is not clinically actionable [86], but may nevertheless cause 
considerable uncertainty and difficulty among carriers of such variants and their 
physicians [96-98]. Missense variants and variants in non-coding parts of the genes 
are especially difficult to interpret and will often fall into the VUS category [83, 99].  
Another argument used in favour of founder mutation tests is that the cost usually has 
been low, compared to Sanger sequencing. With falling prices of sequencing after the 
introduction of NGS, the technical cost is hardly an argument anymore. However, the 
biological and clinical interpretation of rare variants still represents a considerable 
workload in genetic diagnostic laboratories, and requires highly competent personnel 
of which there is scarcity in the public health care system.  
If there is high suspicion of hereditary breast and ovarian cancer, sequencing of the 
total coding region and analysis for large rearrangements should always be performed 
for both genes. A negative result of a founder mutation test does not exclude 
hereditary breast and ovarian cancer.  
1.6 Genetic counselling 
The most common practice of BRCA testing has been referral of selected patients to 
departments of clinical genetics for specialised face-to-face genetic counselling. The 
genetic counselling procedure traditionally includes collection and confirmation of 
family history, risk assessment and eventually BRCA testing followed by a post-test 
counselling session with dissemination of test results and advice concerning 
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surveillance programs and follow-up [100]. Most definitions of genetic counselling 
are based on the work of Fraser from 1974 [101], including the newer definition from 
the National Society of Genetic Counselors in USA [102]:  
“Genetic counseling is the process of helping people understand and adapt to the 
medical, psychological and familial implications of genetic contributions to disease. 
This process integrates the following: Interpretation of family and medical histories 
to assess the chance of disease occurrence or recurrence. Education about inheritance, 
testing, management, prevention, resources and research. Counseling to promote 
informed choices and adaptation to the risk or condition.” 
The definition reflects that the genetic counselling process is closely linked to the 
genetic investigation of the patient and family seeking attention from genetic 
professionals. Most cancer genetic clinics have a team-based approach, in which 
clinical geneticists, genetic counsellors and clinical laboratory geneticists work in 
close collaboration to meet the need of families with hereditary cancer. 
This traditional genetic counselling is usually appreciated by the patients [100], and 
has been shown to reduce the levels of anxiety, depression, psychological distress and 
decisional conflict regarding genetic testing [85, 103, 104].  
1.7 Legal Framework  
In Norway, genetic testing is regulated by formal legislation through “the 
Biotechnology Act” [105]. This Act distinguishes between predictive and diagnostic 
genetic testing: predictive testing requires genetic counselling before, during and after 
testing, while no formal genetic counselling is required for a diagnostic test. 
However, diagnostic BRCA genetic testing will usually have a predictive component 
as well, e.g. in a woman affected with breast cancer the test will be predictive for the 
risk of ovarian cancer and contralateral breast cancer. With respect to this, and the 
patients’ general right to information “…that is necessary to obtain an insight into his 
or her health condition and the content of the health care” as stated in “the Patients’ 
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Rights Act” [106], genetic testing of patients affected by cancer needs to be organised 
in a way that ensures that the need of information and counselling is met.  
1.8 Changing landscape of clinical cancer genetics 
1.8.1 Important events concerning hereditary breast and ovarian 
cancer 
The work constituting this thesis coincided in time with several events that have 
contributed to the increasing demand of BRCA genetic testing and increasing 
awareness about hereditary breast and ovarian cancer among patients, health care 
personnel and the public. Since these events illustrate the rapid development and 
change of practice in the field, some of them will be presented briefly in the 
following.   
In 2013 the American actress Angelina Jolie published an opinion editorial in the 
New York Times, informing that she was carrying a BRCA1 pathogenic variant and 
had chosen prophylactic bilateral mastectomy to reduce her risk of dying from cancer 
[107]. This lead to a global increase in referrals for BRCA testing and prophylactic 
mastectomy, the so-called Angelina Jolie effect [108].  
In 2013, the Myriad monopoly of BRCA-analyses in USA ended, after a patent 
termination by the US Supreme Court [109]. This was followed by a rapid growth in 
commercial laboratories offering genetic testing service [27], and contributed to 
falling costs and increasing access to BRCA testing, including direct-to-consumer 
testing [110].  
In 2014, PARP-inhibitors were approved by US Food and Drug Administration 
(FDA) for treatment of patients with ovarian cancer in USA [76], followed by a 
governmental approval in Norway in October 2015 [77].  
A more local event was organised by the patient organisation The Norwegian Breast 
Cancer Society in October 2016. In their yearly Pink Ribbon Campaign, they had 
hereditary breast cancer as main focus this year, and raised awareness through 
information activities all over the country [111]. 
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1.8.2 Personalised medicine  
The rapid technological development has facilitated extensive molecular 
characterisation of tumours. The valuable insight in tumour biology has permitted 
personalised treatment based on molecular changes in the individual tumour. 
Personalised medicine, or precision medicine, can be defined as adjusted treatment 
based on the individual’s biology, and aims at increased effect and reduced side-
effects of the treatment [112]. Genetic testing is a major component of personalised 
cancer medicine, focusing on molecular changes in the tumour, i.e. somatic genetic 
alterations. However, germline alterations will by nature be present in the tumour as 
well as in normal cells, and are reaching increasing attention as targets for treatment 
[113]. Risk reducing and preventive measures in healthy carriers of germline 
pathogenic BRCA variants are a well-established practice of personalised medicine. 
In addition, there is now an increasing use of diagnostic BRCA testing to tailor cancer 
treatment (see section 1.4.4 and 1.4.5). This is sometimes referred to as “treatment 
focused genetic testing”. Of note, by the increasing use of molecular profiling of 
tumours, more carriers of pathogenic germline BRCA variants will also be identified 
through this new route.  
1.8.3 New procedures for genetic testing and genetic counselling.    
Traditional pre- and post-test genetic counselling in specialised cancer genetics 
clinics is relatively time consuming and the capacity is not dimensioned for the 
expected rise in diagnostic genetic testing of patients with newly diagnosed cancer. 
To meet the increasing demand of diagnostic genetic testing, new service delivery 
models are needed. These new procedures should be dimensioned for large patient 
groups and a short turnover-time from referral/testing to genetic test result.  
The use of telephone counselling facilitates a more rapid process, and has been shown 
non-inferior to face-to-face genetic counselling for persons at increased risk for 
hereditary cancer, when it comes to psychosocial distress [114, 115]. However, 
telephone counselling will often lead to a lower uptake for genetic testing, compared 
to traditional genetic counselling sessions [115, 116]. Alternatively, patients can be 
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offered BRCA testing prior to genetic counselling and take advantage of different 
digital information tools [117]. Studies that have investigated genetic testing of 
unselected patients with breast or ovarian cancer without prior genetic counselling 
have used different ways of delivering information about the genetic test: written 
information only [118], a combination of telephone and written information [48], oral 
information given by non-genetic clinicians [44, 119], and video-based information 
[120]. 
BRCA mutated ovarian cancer may respond to PARP inhibitors regardless if the 
mutation (i.e. pathogenic variant) is germline or somatic. For this reason, some 
groups argue for universal BRCA testing of all ovarian cancers (without pre-test 
genetic counselling), and to proceed with genetic counselling and germline BRCA-
testing if a pathogenic BRCA variant is detected in the tumour [121].  
Regardless of which model has been used, in patients where a pathogenic BRCA 
variant has been found, or in case of a highly suggestive family history for hereditary 
cancer, face-to-face counselling at a cancer genetics clinic should be offered [122]. 
This allows for discussion of the consequences of the results for the patient and the 
family, and also discussion of additional genetic tests when relevant. Predictive 
genetic testing for a known BRCA pathogenic variant should always be performed in 
the context of formal genetic counselling [105].  
While psychosocial aspects have been investigated thoroughly in patients undergoing 
traditional genetic counselling and testing for suspected hereditary cancer [85, 103, 
123, 124], less is known about the psychosocial aspects of offering genetic testing 
without pre-test genetic counselling to unselected women newly affected with breast 
or ovarian cancer.  In contrast to women seeking genetic counselling because of a 
suspicious family history of hereditary breast and ovarian cancer, the women who are 
tested as part of the routine diagnostic work-up in a cancer clinic may be less aware 
of the possibility that their cancer can have a hereditary cause, and thus be less 
prepared for a positive result [125, 126]. Receiving a potential life threatening cancer 
diagnosis is associated with significant distress [127-130], and women who are newly 
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diagnosed with breast or ovarian cancer are often overwhelmed with information and 
choices they have to make [131]. When introducing new service delivery models for 








2. Aims of the project 
The overall aim of this PhD project was to evaluate alternative procedures for 
diagnostic genetic testing and counselling of patients with newly diagnosed breast or 
ovarian cancer, in order to meet the expected increasing need of this health service.   
Specific aims are presented according to the papers that constitute the present thesis: 
Paper I 
The objective of the first publication was to assess the feasibility of offering BRCA 
testing to unselected newly diagnosed patients with breast or ovarian cancer without 
prior face-to-face genetic counselling. We aimed to  
1. Document the uptake of BRCA genetic testing at time of diagnosis  
2. Determine the frequency of BRCA pathogenic variants in unselected patients 
with breast or ovarian cancer 
3. Evaluate the usefulness of existing Norwegian criteria for BRCA genetic 
testing 
4. Investigate the symptoms of anxiety and depression at inclusion and during 
follow-up 
Paper II 
In Paper II we further evaluated the psychosocial aspects in women who were offered 
BRCA testing shortly after a diagnosis of breast or ovarian cancer and aimed to 
5. Document the level and course of cancer related psychological distress  
6. Identify predictors of cancer related psychological distress  
Paper III 
In Paper III we examined in more detail a BRCA1 sequence variant that was detected 
in two patients in the DNA-BONus study. The aim was to 






3. Materials and methods 
Paper I and Paper II are based on results from the same main study, the DNA-BONus 
study, and will be presented together in the materials and methods section. Methods 
and materials for Paper III will be presented separately.  
3.1 Paper I and Paper II: the DNA-BONus study 
3.1.1 Design, recruitment and participants 
We performed a prospective multicentre study with consecutive inclusion from 
September 2012 to April 2015. All patients who were treated for newly diagnosed 
breast cancer (N=893) or ovarian cancer (N=122) were invited to participate in the 
DNA-BONus study, regardless of family history or age at diagnosis. The patients 
were recruited from four hospitals in Western Norway (Haukeland University 
Hospital, Stavanger University Hospital, Haugesund Hospital and Førde Central 
Hospital), including three surgical departments and two gynaecological departments. 
The patients received an information sheet (Appendix 1A) and also had the 
opportunity to call a genetic counsellor if further information was needed. The 
patients could choose to join the genetic testing study (DNA-BONus part 1) with or 
without participating in the associated study of psychosocial aspects (DNA-BONus 
part 2).  
3.1.2 DNA analysis and clinical assessment  
All participants in the DNA-BONus study were tested for 20 pathogenic variants in 
the BRCA1 gene and 10 pathogenic variants in the BRCA2 gene that previously had 
been identified in multiple families with hereditary breast and ovarian cancer in 
Norway (Paper I, Supplementary Table). In addition, the BRCA1 and BRCA2 genes 
were analysed by Multiplex Ligation-dependent Probe Amplification (MLPA) 
technology to detect copy number variation in both genes.  
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The genetic test result was given to the patient by a genetic counsellor around three 
weeks after blood sample collection (Figure 1): 
 Negative BRCA test result and negative family history: information was given 
by letter. 
 Negative BRCA test result and positive family history or personal history 
fulfilling criteria for BRCA sequencing: information by phone call and letter. 
The patient was offered genetic counselling in an outpatient clinic. Based on 
collection of traditional extended family history and confirmation of cancer 
diagnoses in relatives, selected patients were then offered extended genetic 
testing with Sanger sequencing of all exons and flanking intron sequences in 
both BRCA1 and BRCA2, according to current clinical guidelines at that time.  
 Positive BRCA test result: information by phone call. The patient was offered 
genetic counselling in an outpatient clinic within maximum 2 weeks, and a 
second blood sample was collected to verify the result of the test. Relatives at 
risk were subsequently informed by the index patient and were offered genetic 
counselling and testing. 
In addition, the results were reported to the doctor who included the patient in the 
study.  
All patients were categorised according to the current Norwegian genetic test criteria 
(Table 1, 2010 criteria) before BRCA testing was performed, based on clinical 
information retrieved from their medical record and self-reported structured family 
history given on the request form for DNA analysis (Appendix 1B). The participants 
were in addition rated by the Manchester scoring system for BRCA testing, version 1 
[132]. The system takes into account age dependent occurrence of cancer in the 
breasts, ovaries, pancreas, and prostate in all family members under the condition of 
an autosomal dominant inheritance pattern. In general, a higher Manchester score 
indicates higher probability of a pathogenic BRCA variant being present, e.g. a score 
above 15 corresponds to 10% probability, a common used threshold for BRCA testing 
in many countries [91, 132]. 
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Patient received a phone call from a 
genetic counsellor and was invited for 
genetic counselling
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result by a letter from the 
genetic counsellor
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Personal or family history indicating 




about the genetic test
Blood sample withdrawal at 
the clinical department
Analysis result report was sent 
to the genetic department 
The patient’s physician received
 a copy of the result report
 
Figure 2 
Flow chart showing the recruitment of patients and the reporting of genetic test results in the 
DNA-BONus study  
 
3.1.3 Psychosocial measurements 
Participants who consented to participate in part 2 of the prospective DNA-BONus 
study were asked to fill in questionnaires at three measurement points. The first 
questionnaire was given to the participants along with the invitation to the study (T1). 
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The second and third questionnaires were mailed to the participants one week (T2) 
and 6 months (T3) after disclosure of the BRCA test result, respectively (Figure 3). 
 
Figure 3 
Timeline showing data collection and questionnaires used in the prospective DNA-BONus 
study, part 2  
*
Sociodemographic variables: education, biological children, cohabitating status, employment status 
 
Outcome variables 
Anxiety and depression 
We used the Hospital Anxiety and Depression Scale (HADS) to measure symptoms 
of anxiety and depression as an outcome in Paper I. HADS was originally developed 
to screen for anxiety and depression among non-psychiatric patients [133]. It 
comprises two subscales for symptoms of anxiety and depression, respectively, each 
with 7 items to be scored on a four-point (0-3) scale, giving a range of sub scores 
from 0 to 21. Subscale scores equal to or above eight were used as cut-off for 
defining higher levels of anxiety and depression [134].  
Subjective distress 
We defined distress as intrusive thoughts and avoidance behaviour, and used the 
Impact of Event Scale – 15 (IES-15) to measure this outcome in Paper II [135]. IES-
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15 is a 15 item questionnaire comprising two subscales [135]. The intrusion subscale 
(IES-I) includes seven items and is scored from 0-35, and the avoidance behaviour 
subscale (IES-A) consists of eight items and is scored from 0-40. The subscale scores 
are considered low in the range of 0-8, moderate at 9-19 and severe at 20 and above. 
Intrusion symptoms include unbidden thoughts and images both awake and during 
sleep, waves of overwhelming feelings of fear and repetitive behaviour. Avoidance 
responses include denial of the meaning and consequences of the threatening event, 
blunted sensation, emotional numbness and attempts to block out unpleasant feelings 
and memories. IES was originally developed to measure current stress reactions after 
any specific traumatic event; in our study ‘cancer diagnosis’ was defined as the 
specific event.  
Socio-demographic characteristics 
At T1 we included questions about sociodemographic variables; i.e. education level, 
biological children, cohabitation and employment status. 
Social support 
The concept of perceived social support was measured by the version of the 
Interpersonal Support Evaluation List (ISEL) used by King and colleagues [136], 
which consists of 30 items that are answered with a score from 1-4. This version 
measures five different and independent sources for experienced social support: 
appraisal support, self-esteem support, group belonging support, emotional closeness 
support, and tangible aid [85, 136, 137]. The average sum score for each participant 
was used.  
Decisional conflict 
We used the Decisional Conflict Scale (DCS) to measure the study participants’ 
ambivalence toward making a choice of undergoing BRCA testing [138, 139]. This 
scale contains 16 items, which is scored from 0-4. Three dimensions of decisional 
conflict are measured: uncertainty about selection of alternatives (3 items), specific 
factors contributing to uncertainty (9 items) and perceived effectiveness of decision 
making (4 items). Higher scores indicate higher levels of decisional conflict. The sum 
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score of all items was converted to a 0-100 scale, where total scores below 25 are 
associated with low level of decisional conflict and scores above 37.5 are associated 
with problems in implementing decisions.  
3.2 Paper III 
3.2.1 Patient materials and clinical assessment 
We recruited families from Haukeland University Hospital, and Oslo University 
Hospital in Norway, Hospices de Lyon in France, and Allegheny Health Network, 
Pittsburgh, PA in USA, in which the BRCA1 c.5407-25T>A variant had been 
identified in at least one family member before June 1
st
 2019. We collected clinical 
information and family history from the patients’ medical files. The family histories 
were rated by the Manchester Scoring System version 3 [140].   
3.2.2 Control materials and variant allele frequency 
Anonymous blood donors from Haukeland University Hospital were used as controls 
for DNA and RNA analyses. The variant allele frequencies were retrieved from an in-
house database and from different populations using the gnomAD database [141]. 
3.2.3 DNA, RNA and protein analyses  
cDNA synthesis was performed using RNA purified from patient-derived blood, 
breast and ovarian tissue. For RNA splicing analysis, cDNA was amplified by PCR, 
followed by Sanger sequencing and next generation sequencing (NGS). To assess for 
a potential leakage of normal full-length transcript from the variant allele leading to 
biallelic expression of full-length transcript, a PCR fragment including the SNP 
BRCA1 c.4837A>G (rs1799966) was amplified from carriers heterozygote for this 
SNP. Full transcriptome sequencing of RNA from blood was performed using TruSeq 
and HiSeq 4000 Sequencing System (Illumina). For protein analysis, plasmid 
constructs were generated by cloning wild-type and p.(Gly1803GlnfsTer11) BRCA1 
cDNA into a eukaryotic expression vector. After transfection into HeLa cells, lysates 
were analysed by qPCR and Western blot.  
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3.3 Statistical methods 
Descriptive statistics were given as mean values, standard deviations (SD), standard 
error of means (SEM), range, and proportions.  
McNemar’s exact test was used for paired categorical variables.  
The independent samples t-test was used to compare the means of two independent 
groups.  
The chi- square test was used compare proportions in two independent groups.   
The paired samples t-test was used to compare changes over time in mean scores of 
IES and HADS. 
Mixed linear modelling was used to identify the characteristics related to the IES-I 
and IES-A and to test the changes of IES-I and IES-A over time. All predictors were 
entered into the mixed linear models to assess both main effects and possible 
interactions with time. The regression analyses were run backwards stepwise, both 
with and without interaction with time.  
Nonresponse was analysed with multiple logistic regression analysis. 
 
The significance level was set at 0.05 for all statistical tests. Missing values were 
replaced by the individual’s own average score for each questionnaire if 60% or more 
of the items were filled in by the respondents. The statistical analyses were performed 
using IBM Statistical Package for the Social Sciences (SPSS) using versions 22.0 
(Paper I) and 24.0 (Paper II and Paper III). 
 
3.4 Ethical considerations 
Research involving humans always requires a careful consideration of the procedures 
to be used to protect the rights and confidentiality of human beings. The studies in 
this PhD project have been carried out according to the Declaration of Helsinki [142]. 
All subjects in the prospective DNA-BONus study (Paper I and Paper II) gave their 
written consent based on an information sheet. They were also offered to call a 
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genetic counsellor, if they had questions regarding the study or the written 
information. The DNA-BONus study was preceded by a long-standing debate in 
Norway about whether and how an offer of diagnostic genetic testing for patients 
with breast/ovarian cancer should be introduced [94]. The Norwegian Directorate of 
Health concluded that more knowledge was needed before genetic testing of all 
patients with breast or ovarian cancer could be implemented in clinical practice. The 
present study was a response to this call for more knowledge and served as a 
preparation for the anticipated increasing demand for genetic testing of newly 
diagnosed patients with cancer.   
The DNA-BONus study was approved by the Regional Committee for Medical and 
Health Research Ethics, REK-Vest 2012-60 and 2012-62, and was also evaluated 
positively by the Norwegian Directorate of Health (Paper I and II).  
The study of BRCA1 c.5407-25T>A was evaluated by the Regional Committee for 
Medical and Health Research Ethics, REK Nord 2018/996, and classified as a quality 
of care study (Paper III).  
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4. Results 
The main results of the three papers constituting this thesis are presented below. The 
results of Paper I and Paper II (the DNA-BONus study) will be presented together, 
and the results of Paper III will be presented separately. 
4.1 Paper I and Paper II: the DNA-BONus study 
4.1.1 Study sample 
A total of 1,015 patients with either breast cancer (N=893) or ovarian cancer (N=122) 
were offered BRCA testing at the time of cancer diagnosis. In total, 488 women 
completed genetic testing (Figure 4); 405 (45.4%) of the breast cancer patients and 83 
(68.0%) of the ovarian cancer patients. More than half of the participants (55.7%) 
fulfilled at least one of the Norwegian 2010 BRCA test criteria (Table 1). After 
exclusion of 242 patients who got access to a website and an information video as an 
intervention (results not part of this thesis) and one patient who turned out to be 
diagnosed not recently, but nine years earlier, 772 invited women were eligible and 
309 gave consent for the psychosocial substudy in Paper II (Figure 4). Since Paper I 
was published before all respondents had answered the questionnaires at T3, the 
HADS analyses in Paper I were based on a smaller subset of participants (N=215).  


















242 had access to information 
video and web site 
(«intervention»)





 T1 to T3
 
Figure 4 
Flow chart showing inclusion of study samples for the different parts of the DNA-BONus 
study (Paper I and Paper II) on women having genetic testing shortly after a diagnosis of 
breast or ovarian cancer  
 
4.1.2 Genetic test results 
We found a pathogenic BRCA variant in seven (1.7%) of the 405 patients with breast 
cancer and 19 (22.3%) of the 83 patients with ovarian cancer. All carriers of a 
pathogenic BRCA variant met the Norwegian 2010 BRCA test criteria.  
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Table 2 Sociodemographic and main medical variables for participants in the DNA-
BONus study: study sample of Paper I, Paper II, and dropouts 
 
Abbreviations: T1/T3: first and last time points for questionnaires in the study; SD: standard 
deviation; ISEL: Interpersonal Support Evaluation List (range: 1-4); DCS: Decisional Conflict 
Scale (range:0-100); IES: Impact of Event Scale (Intrusion subscale range: 0-35; Avoidance 
subscale range: 0-40); HADS: Hospital Anxiety and Depression Scale (range: 0-21) 
*range: 2-unlimited 
4.1.3 Psychological outcomes 
Table 3 shows the results from the HADS (Paper I) and IES-15 (Paper II) 
questionnaires. The mean HADS subscale score for anxiety symptoms decreased 
















N = 309 
Dropouts from 
T1 to T3 
Paper II 
N = 52 
Age, years, mean (SD) 57.3 (12.3) 61.1 (13.9) 56.1 (11.5) 56.8 (12.7) 
Manchester score*, 

















Breast cancer, n (%) 335 (83.1) 76 (80.9) 259 (83.8) 43 (82.7) 
Ovarian cancer, n (%) 68 (16.9) 18 (19.1) 50 (16.2) 9 (17.3) 
Genetic test criteria 


















               variant, n (%) 21 (5.2) 6 (6.4) 15 (4.9) 2 (3.8) 
Education, n (%) 
  
  
    
Primary school 
  
  50 (16.5) 12 (23.5) 
High school 
  
  115 (38.0) 14 (27.5) 
University 
  
  138 (45.5) 25 (49.0) 
Missing, n 
  




Employed, n (%) 
  
  189 (62.2) 24 (47.1) 
Missing, n 
  




Having biological  
              children, n (%)    
  272 (89.2) 44 (88.0) 
Missing, n 
  




Cohabitant, n (%) 
  
  218 (71.2) 29 (56.9) 
Missing, n 
  




ISEL at T1, mean (SD) 
  
  3.46 (0.47) 3.40 (0.4) 
DCS at T1, mean (SD)  
  
  19.0 (15.2) 22.5 (17.1) 
Missing, n     5  1  
IES-I T1, mean (SD) 
  
  14.6 (9.4) 17.6 (10.7) 
Missing, n     1    
IES-A T1, mean (SD) 
  
  12.7 (9.2) 16.0 (10.0) 
HADS-A T1, mean (SD) 
  
  6.6 (4.3) 7.9 (4.8) 
Missing, n     15  1  




(3.1) 4.3 (3.7) 
Missing, n     3    
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disclosure of the BRCA test result (p < 0.001). During the observation period there 
was no significant change in the mean depression symptoms score, which was low at 
all measurement points.  
We also found a significant decrease in cancer related psychological distress from T1 
to T3, as measured with IES-15. The mean IES-Intrusion score decreased from 14.6 
at T1 to 12.1 at T2 (p < 0.001) and with a further significant decrease to 9.7 at T3 (p 
< 0.001) (Table 3). The mean IES-Avoidance score was 12.7 at T1, decreased 
statistically significantly to 10.2 at T2 (p<0.001), but with no further statistical 
significant decrease from T2 to T3 (mean score 9.7).  
Table 3 HADS and IES subscale scores at different time points in women undergoing 
genetic BRCA testing in the DNA-BONus study 
Abbreviations: T1/T2/T3: time points for questionnaires in the study; HADS: Hospital Anxiety 
and Depression Scale; SD: standard deviation; IES: Impact of Event Scale  
 
The results of the mixed linear regression analyses showed that younger age, shorter 
time since diagnosis, lower level of perceived social support, and a diagnosis of 
ovarian cancer were predictors of higher IES-Intrusion and IES-Avoidance (Paper II, 
Table 3). In addition, two additional predictors of higher IES-Intrusion were found:  






of genetic test 
result 
(T2) 
Six months  
after disclosure 
of genetic test 
result 
(T3) 
I HADS-Anxiety (scale 0-21), n 213 191 167 
 Subscale score, mean (SD) 6.84 (4.28)   5.29
 
(4.06)    4.88
 
(3.86) 
 Score ≥ 8, n (%)  85 (39.9) 45 (23.6) 33 (19.8) 
I HADS-Depression (scale 0-21), n 215 190 169 





 Score ≥ 8, n (%)  22 (10.2) 19 (10.0) 18 (10.7) 
II IES-Intrusion (scale 0-35), n 308 277 257 
 Subscale score, mean (SD) 14.6 (9.4) 12.1 (9.3) 9.7 (8.3) 
 Score ≥ 20, n (%)   99 (32.1)   68 (24.5)   36 (14.0) 
II IES-Avoidance (scale 0-40), n 309 277 256 
 Subscale score, mean (SD) 12.7 (9.2) 10.2 (8.2) 9.7 (8.3) 
 Score ≥ 20, n (%)   73 (23.6)   44 (15.9)   41 (16.0) 
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higher level of decisional conflict regarding the genetic test, and living with a partner 
(Paper II, Table 3).  
4.2 Paper III: The intronic BRCA1 c.5407-25T>A variant  
We identified 20 different families with the intronic BRCA1 c.5407-25T>A variant. 
Among carriers of the variant, the mean age at breast cancer diagnosis (N=12) was 
49.9 years (SD 9.9) and the mean age at ovarian cancer diagnosis (N=11) was 60.4 
years (SD 11.3). The mean Manchester score in the 20 rated families was 16.4 (SD 
9.2).  
The BRCA1 c.5407-25T>A variant was identified in 1/400 anonymous blood donors, 
and 0/784 in-house (non-cancer) diagnostic exomes. In the gnomAD database 
(v2.1.1), the allele frequency of this variant is reported to be 1/141,398 in total and 
1/64,566 in non-Finnish European population [141].  
Sequencing of cDNA from blood, breast and ovarian tissue showed that BRCA1 
c.5407-25T>A leads to skipping of exon 22. The exon skipping results in a frameshift 
and predicts a truncated BRCA1 protein (Gly1803GlnfsTer11). BRCA1 c.5407-
25T>A carriers heterozygous for the SNP rs1799966 (c.4837A>G) were shown to 
express a small amount of correctly spliced transcript (including exon 22) originating 
from the BRCA1 c.5407-25T>A allele (Paper III, Figure 2). An NGS-based semi-
quantitative analyses of patient-derived RNA indicated that 10-13% of total full-
length transcript was generated from the variant allele in blood (N=3) and 20% in 






5.1 Methodological considerations 
5.1.1 The DNA-BONUS study design (Paper I and II) 
For the DNA-BONus study, a prospective longitudinal study design was chosen, 
since we were interested in the outcome of offering genetic testing shortly after a 
diagnosis of breast or ovarian cancer. Prospective design is considered a strength, 
compared to retrospective or cross-sectional design. Another strength was that we 
included all patients with newly diagnosed breast or ovarian cancer; the patients were 
not selected by age or family history. However, we systematically collected family 
history from all participants, which was also a strength of our study.  
Our study was designed for integration in daily practice at clinical departments 
diagnosing and treating patients with breast or ovarian cancer. In this way, the study 
could serve as a preparation for the expected increased need for treatment focused 
genetic testing in the future. However, a limitation with studies in a “naturalistic 
setting” like this is that the study conditions are more challenging to standardise. Five 
different clinical departments recruited participants to the study, and some variation 
in logistics was inevitable, like e.g. timing of the invitation, wording by the local 
nurse or physician, blood sampling facilities etc. Because of ongoing inclusion of 
breast cancer patients to another research project, one of the departments invited to 
collaborate in the DNA-BONus study declined, resulting in patients with breast 
cancer were not recruited from the southern part of our region where founder 
mutations are most prevalent. Consequently, the breast cancer cohort and ovarian 
cancer cohort in our study were not drawn from the exact same geographical 
population. 
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5.1.2 DNA analysis (Paper I) 
For the DNA-BONus study we developed a screening test using TaqMan Low 
Density Arrays to screen for 30 variants previously detected in multiple families in 
Norway. The selection of variants to include in the test was mainly based on a survey 
carried out by the Norwegian Directorate of Health in 2009 of all BRCA pathogenic 
variants detected in Norway. MLPA was added to the screening test, since several 
Norwegian families previously had been identified with large rearrangements in the 
BRCA genes.  
The disadvantage of using a test with a limited number of predefined variants is of 
course that the test will not detect all pathogenic variants, some carriers will be lost if 
this was the only test performed. To ensure that those participating in our study had 
access to equal standard of genetic testing as they would have had through ordinary 
health care, participants fulfilling existing clinical criteria for sequencing (Table 1) 
were offered sequencing of the whole coding region of BRCA1 and BRCA2 after 
genetic counselling. Furthermore, sequencing of BRCA1 and BRCA2 cannot exclude 
pathogenic variants in other genes, and this was our rationale for having a low 
threshold for the genetic counsellor to contact patients if their personal or family 
history indicated that other genes should be analysed (e.g. PTEN or TP53).  
There were several reasons for choosing a limited screening test instead of full BRCA 
sequencing or multigene panel test in this study. Firstly, genetic testing of an 
unselected group of patients with low a priori risk of having a pathogenic variant, 
would potentially lead to a high number of variants of uncertain clinical significance. 
We chose to be cautious, when expanding the target group for genetic testing through 
our new model, and therefore only included pathogenic BRCA variants that had 
already been identified in Norwegian patients. This was also in line with the 
conclusion from the Norwegian Health Authorities after the national debate preceding 
our study [94]. Secondly, we needed a test that could be easily integrated in the 
existing pipeline in our diagnostic laboratory, with a response time less than three 
weeks. Finally, the cost of full sequencing in all patients was too high for our limited 
research budget. 
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5.1.3 Family history assessment (Paper I and III) 
For Paper I, information about family history was collected through a structured 
questionnaire on the request form for genetic testing (Appendix 1B). This information 
was used to categorise the study participants according to the Norwegian 2010 BRCA 
test criteria and to select patients for invitation to clinical genetic counselling and 
further genetic testing. In addition, the family histories were rated by the Manchester 
Scoring system (MSS), a tool that has been developed to identify families at high risk 
of having a pathogenic BRCA variant [132]. The system was first published in 2004 
(MSS1) [132] and was revised in 2009 to include information about tumour 
pathology (MSS2) [143], with a second revision in 2017 (MSS3) [140]. Because of 
limited information about pathology we used the first version, MSS1, when rating all 
participants in Paper I. In addition, carriers of pathogenic variants were recalculated 
with MSS2 after collection of pathology information and confirmation of cancer 
diagnoses in the family.  
In Paper III, the third version of the Manchester scoring system (MSS3) was used. 
Although the system was not developed with variant interpretation in mind, we found 
it useful in both Paper I and Paper III, to quantify the burden of relevant cancer in the 
families. Of note, it has also been used by the group developing the system, in 
interpretation of a BRCA1 splice variant [144].  
The families included in Paper III were mainly from our own department, but in 
addition we recruited families from collaborators who had access to families with the 
same variant. The BRCA1 c.5407-25T>A variant is rare, and the selection of families 
was based on the availability of DNA test results and clinical and family information. 
Ideally, a segregation analysis would have been performed, but unfortunately the 
sizes of the individual families were too small.  
5.1.4 Psychosocial measurements (Paper I and II) 
For the psychosocial measurements we used pre-existing and validated 
questionnaires.  By using well known questionnaires, the quality is often established, 
and the strength is that this gives the opportunity to compare the results with previous 
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studies. The reliability of the selected instruments has been satisfying in previous 
studies, and this was also the case in our study.  The Cronbach’s alpha value had a 
range of 0.83 to 0.88 for HADS-Anxiety, 0.80 to 0.86 for HADS-Depression, 0.93 to 
0.95 for IES-Intrusion, and 0.86 to 0.87 for IES-Avoidance at the three assessments. 
For the predictor variables the Cronbach’s alpha values were 0.92 (ISEL), and 0.96 
(DCS).    
Ideally, the results of the DNA-BONus study could be generalised to all patients 
offered genetic testing short time after a diagnosis of breast or ovarian cancer. 
However, we only had data on the 488 patients (48 % of invited patients) actually 
pursuing genetic testing. Due to ethical regulations, we could not collect information 
about the patients who did not consent to the study. However, by using data from the 
Cancer Registry of Norway we knew that participants in our study were younger 
(mean age 56.9 years at breast cancer diagnosis and 60.5 years at ovarian cancer 
diagnosis) than the average patients diagnosed with breast or ovarian cancer in 
Norway. According to the Norwegian Cancer Registry, the mean age at breast cancer 
diagnosis was 62.2 years and the mean age at ovarian cancer was 64.8 years in the 
years 2012-2015 [145]. For the psychosocial substudy, the data were collected in an 
even smaller subgroup, i.e. the results in Paper II were based on answers from 40% of 
those invited (309/772). The response rate for the psychosocial substudy among those 
undergoing genetic testing was 77% (309/403). In a multiple logistic regression of 
genetic test only versus genetic test and responding to questionnaire on age, 
Manchester score, diagnosis, genetic test criteria and mutation carrier status, only age 
was significant. The mean age was statistically significantly lower among participants 
also answering the questionnaires (56.1 years) compared to those who only 
participated in the genetic testing study (61.1 years) (p = 0.001). This indicates a 
selection bias toward younger patients for both the genetic testing study and even 
more so for the psychosocial substudy. On this background we could argue that our 
results may not be representative for the older patient population. We also did a 
multiple logistic regression analysis in all that responded at T1 (n = 309) of dropping 
out at T3 on age, Manchester score, diagnosis, genetic test criteria, mutation carrier 
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status, education, employment, having biological children, having a partner, and T1 
mean values for ISEL, DCS, IES-I, IES-A, HADS-A and HADS-D. We found that 
participants who dropped out of the psychosocial study from the first (T1) to the last 
(T3) questionnaire were characterised by lower levels of education (p = 0.048), lower 
share of employment (p = 0.032), and lower share of cohabitation (p =0.034). Due to 
a small number of patients identified with a pathogenic BRCA variant, no specific 
conclusion could be drawn for this particular subgroup.   
5.1.5 Assessment of the splice variant BRCA1 c.5407-25T>A 
(Paper III) 
To assess the effect of the intronic BRCA1 c.5407-25T>A variant on splicing, we 
analysed RNA extracted from carriers of the variant, and showed that the variant 
leads to skipping of exon 22. We had access to samples from blood as well as from 
breast and ovarian tissue, the latter being the most relevant tissue concerning the 
cancer risk for carriers of pathogenic BRCA1 variants.  Our RNA analyses showed 
similar results in all three tissue types, indicating that blood is a relevant source of 
RNA for analyses of BRCA1, with respect to breast and ovarian cancer. This is in 
accordance with previous studies [146, 147]. 
The access to patient derived RNA was a strength in our study, compared to e.g. a 
minigene assay, which is often used when appropriate patient material is not 
available. In a minigene assay a fragment including the variant sequence of interest 
and flanking intronic sequences is amplified by PCR from patient genomic DNA and 
cloned into a minigene vector. Following transfection into cultured cells, the 
transcripts generated from the variant construct are analysed and compared to wild-
type. The minigene assay has the advantage that expression from the allele 
harbouring the variant can be analysed separately, without contribution from the 
wild-type allele. However, this is an artificial in vitro assay, which does not 
necessarily reflect the splicing process in vivo.  
The presence of a coding SNP (c.4837A>G) in BRCA1 exon 15 enabled us to 
document that some BRCA1 full-length transcripts were also expressed from the 
c.5407-25T>A variant allele. Furthermore, we were able to perform a semi-
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quantitative analysis of the amount of full-length BRCA1 transcript including exon 22 
that was expressed from the variant allele, through NGS-based sequencing of only the 
PCR products containing exon 22. When interpreting splice variants, the detection 
and quantification of “leakage” of full-length transcript from the variant allele is very 
important, since this can lead to maintenance of some tumour suppressor effect if the 
normal allele is disrupted by a somatic mutation. Our full transcriptome RNA 
sequencing was not very successful, as only a limited number of reads mapped to the 
BRCA1 sequence. This could have been improved by increasing the number of reads, 
but high cost made this unjustifiable. A better approach would be targeted enrichment 
of the BRCA1 gene before sequencing. We did an attempt on this, but unfortunately, 
we did not succeed.  We will modify the protocol in future experiments. Furthermore, 
sequencing using “long read” platforms like Oxford Nanopore Technologies may 
solve some of the problems with quantification of different transcripts [148]. 
Multifactorial likelihood analyses are very helpful tools commonly used in evaluation 
of variants of uncertain significance in BRCA1 [88, 149, 150]. These methods 
combine data from different independent sources like histopathology of tumours, 
family history, co-segregation with the disease in the family, and observed co-
occurrence of the variant with a pathogenic BRCA1 variant in trans. This is a 
powerful tool when enough data is available; however, for many rare variants the 
amount of data input will not be sufficient to reach a conclusion regarding 
pathogenicity [151, 152]. Furthermore, these methods have been designed to 
distinguish between benign sequence variants and pathogenic high-penetrance 
variants, and are not well suited for variants of potential reduced penetrance. An 
attempt was made to perform a multifactorial likelihood analysis on the BRCA1 
c.5407-25T>A variant, however the model failed for this variant just like it had done 
for other intermediate risk variants (Adrien Buisson, personal communication).  
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5.2 Discussion of specific findings 
5.2.1 Genetic testing in newly diagnosed patients with breast or 
ovarian cancer 
In our study, we found an uptake rate of genetic testing among newly diagnosed 
patients with breast cancer of 45%. For patients with ovarian cancer, the uptake rate 
was 68%. There are few comparable studies on uptake of BRCA testing in unselected 
patients newly diagnosed with breast or ovarian cancer. Nilsson et al. performed a 
study similar to ours and found that 67% of unselected patients with breast cancer 
accepted the offer of BRCA testing [118]. Kurian et al. performed a large 
retrospective survey among women two months after primary breast surgery, and 
found that 66% of the patients wanted genetic testing [153]. The uptake rate is 
generally higher among patients with ovarian cancer, with the highest rate reported 
(100%) in the mainstream cancer genetics programme in UK [119]. Several factors 
could affect the patients’ decision to undergo genetic testing soon after diagnosis. Our 
study was performed before the approval of treatment with PARP-inhibitors for 
BRCA-deficient ovarian cancer, and the genetic test results would in most cases not 
have an effect upon the treatment of the patient. When genetic testing is performed 
mainly to inform cancer treatment, a higher uptake rate would be expected. Genetic 
counselling is by tradition non-directive with no right and wrong decisions 
concerning genetic testing. However, patients tend to follow their physician’s advice 
when it comes to treatment decisions [154], and this could also impact their choice of 
having treatment focused genetic testing. Contrary, “my doctor didn’t recommend it” 
was the most common reason high-risk patients reported for not having genetic 
testing in the survey of Kurian et al [153]. In our study, the main information was 
given in the written information letter, but we cannot rule out that a difference in 
wording or other local factors may have influenced the patients’ final choice to 
undergo testing (see section 5.1.1).  This could e.g. explain the higher uptake rate 
observed for patients of the smaller hospitals compared to Haukeland University 
Hospital (see Table 4).  
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Table 4. Uptake rate of genetic testing at the different participating clinical 
















Patients invited, n 671 117 105 58 64 
Blood samples 
returned, n (%) 283 (42.2) 65 (55.6) 57 (54.3) 35 (60.3) 48 (75.0) 
 
At Haukeland University Hospital multiple research studies are ongoing at all times, 
and some patients may have chosen to participate in other studies instead of ours. The 
information about different studies comes on top of all other information related to 
the diagnosis, and for some patients the total information load can be overwhelming 
[131], resulting in the information about genetic testing is lost “in the crowd”.   
We found a lower mean age of participants in our study compared to average patients 
with breast or ovarian cancer diagnosed in Norway in the same period (se section 
5.1.4). We also found that a majority of the participants were eligible for diagnostic 
BRCA testing according to the national guidelines. This indicates that patients with 
higher risk of carrying a BRCA pathogenic variant were more likely to undergo 
genetic testing in our study. Our findings are in line with other studies, reporting that 
younger age and higher presumed risk of carrying a BRCA pathogenic variant are 
predictors of BRCA testing uptake [153, 155].  
Practical issues like easy access to blood sampling services can also affect the total 
share of patients pursuing genetic testing. For example, studies have shown that more 
patients go on with the genetic test if it is performed immediately after face-to-face 
genetic counselling as compared to telephone based genetic counselling [114]. 
In this study, we found a high frequency of pathogenic BRCA variants among patients 
with ovarian cancer (22.3%). Other studies have reported a frequency of 8.0-28.5% in 
unselected cohorts of ovarian cancer, with the highest numbers reported in 
populations with high prevalence of founder mutations [31, 48-51]. Among our breast 
cancer patients, the frequency was among the lowest reported, 1.7%, similar to what 
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was recently reported in a large study from Sweden (1.8%) [43]. A study from Oslo 
found a frequency of 3.1% [44] among unselected patients with breast cancer. In 
other populations, the carrier frequency varies, and the highest frequencies have been 
found in Asia (4.7-5.4%) [45, 47] and in cohorts including patients of Ashkenazi 
Jewish descent (6.1%) [46]. While more than half of the patients with ovarian cancer 
in our study were recruited from the southern part of our health region, this was the 
case for only 14% of the patients with breast cancer, resulting in a less prominent 
founder effect among the included breast cancer patients. Also, because of our two-
step model of genetic testing, we cannot rule out that rare pathogenic variants may 
have been missed in patients not fulfilling criteria for sequencing of the complete 
coding regions of BRCA1 and BRCA2.  
Clinical criteria for genetic testing are constantly changing and subject of debate 
[156-158]. The overall trend is that testing criteria are expanding, as the cost of 
genetic testing continues to fall. Moreover, the genetic test result is becoming 
increasingly important for treatment decisions. Until recently, a commonly used 
threshold for BRCA testing eligibility has been a 10% chance of finding a pathogenic 
variant [91]. We investigated the usefulness of the Norwegian criteria for BRCA 
genetic testing (Table 1), and found that all patients with identified pathogenic BRCA 
variants in the DNA-BONus study fulfilled one or more of the 2010 BRCA test 
criteria. Thus, the criteria seemed sufficient to detect most of the carriers in the DNA-
BONus study. However, because of the high frequency of pathogenic BRCA variants 
among patients with ovarian cancer we recommended that all patients with ovarian 
cancer should be offered BRCA genetic testing, regardless of family history and age 
(Paper I). The Norwegian Health Authorities has implemented this recommendation 
in national guidelines since 2015 [74], and several countries have similar guidelines 
[159, 160]. For any patient with ovarian cancer, the likelihood of having a germline 
pathogenic BRCA variant exceeds 10% in the Norwegian and in many other 
populations.  
However, the likelihood of being a BRCA carrier is much lower for a patient with 
breast cancer, only 1.7% in our study. We identified a pathogenic BRCA variant in 
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3.0% of patients with breast cancer fulfilling the Norwegian BRCA test criteria. This 
indicates that the Norwegian criteria already have set a low threshold for testing of 
patients with breast cancer, and the findings in our study did not provide a basis for 
changing the current recommendations. Similar to our results, a study from US on 
488 unselected patients with breast cancer found that all (N=30) identified BRCA 
carriers fulfilled the 2015 National Comprehensive Cancer Network (NCCN) criteria, 
which have many similarities to the Norwegian 2010 criteria [46, 161].  
The Norwegian Health Authorities recently approved a change in the Norwegian 
criteria, stating that all women diagnosed with breast cancer before the age of 60 
years should be offered BRCA genetic testing, regardless of family history or tumour 
pathology [64]. This change was mainly based on the result from the aforementioned 
study from Oslo, where they found similar sensitivity (around 90%) of this age 
criterion alone as for the more complex clinical test criteria [44]. The change results 
in more than a doubling of the number of women with breast cancer eligible for 
genetic testing. The hope is that simplifying of the criteria will lead to more genetic 
tests ordered by the breast surgeons and oncologists.  
The discussion continues whether criteria are needed for patients with breast cancer, 
or if the time now has come to offer all patients with breast cancer genetic testing [44, 
162, 163]. Despite falling costs and broadened criteria for genetic testing, there is still 
a substantial underuse of genetic testing of patients with breast and ovarian cancer. 
Several studies have shown that a significant share of patients fulfilling BRCA genetic 
test criteria do not undergo genetic testing [156, 164-167]. There is no help in 
refining criteria that in an ideal world would identify all carriers, if individuals 
meeting those criteria are not tested. Lack of physicians’ referral to genetic 
counselling has been reported as a main barrier for genetic testing of patients with 
breast and ovarian cancer [153, 165, 168]. Even without formal pre-test genetic 
counselling as a requirement for diagnostic genetic testing, the recommendation (or 
not) from the patient’s physician can influence the likelihood of going forward with 
genetic testing [153].   
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The Norwegian Biotechnology Act is currently under revision. One of the proposed 
changes specifies that the purpose of the genetic test determines whether it is 
predictive or not; e.g. BRCA testing of a woman already affected by breast cancer is 
considered a diagnostic test, even if a positive result will be predictive for her risk of 
ovarian cancer. Another proposed change is that genetic counselling should be 
differentiated and adjusted to the specific situation in which genetic testing is 
performed. These two changes could facilitate more diagnostic genetic testing 
performed by non-genetic health care professionals.  
However, the rapid development in genetics has generated a knowledge gap among 
non-genetic physicians that needs to be filled [169]. Education of key providers like 
oncologists, surgeons and gynaecologists can potentially increase the rate of patients 
being tested [119]. Education may also be of great importance to avoid unnecessary 
“over-testing”. It is a paradox that there are still thousands of unrecognised carriers of 
highly penetrant pathogenic variants in BRCA1 or BRCA2, and at the same time there 
are thousands of people spending money, time and worries on genetic testing for 
variants with uncertain associations with cancer risk through less justified genetic 
testing. While health professionals, researchers, and health authorities develop 
evidence-based guidelines for genetic testing, counselling and follow-up, commercial 
interests are now playing an increasing role in this field. Companies offer direct-to-
consumer tests for hereditary cancer risk, with highly variable content and quality, 
and usually with no associated genetic counselling service [110, 170]. Clinical 
genetic departments experience an increasing number of referrals of people who have 
ordered genetic self-tests, and who needs help to interpret the result. There are several 
reports of these results being uninformative, directly wrong or at the best inaccurate 
[171, 172].  
Establishing good procedures and securing access for genetic testing in health care is 
therefore important to reduce “leakage” of patients to direct-to-consumer testing that 
causes more burden than benefit both for the patients and the community. A new 
approach for improving genetic testing for cancer predisposition is population based 
genetic screening. Although yet not implemented in form of national screening 
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programs, this approach is gaining increasing support among experts in the field 
[173-175].  
5.2.2 Psychosocial aspects of genetic testing shortly after cancer 
diagnosis 
Overall, the study participants who underwent genetic testing shortly after receiving a 
diagnosis of breast or ovarian cancer seemed to cope well with the new and 
simplified procedure for genetic testing. In accordance with this, a recent Swedish 
study reported high patient satisfaction with a similar procedure in patients newly 
diagnosed with breast cancer [176]. In our study the mean values of anxiety and 
depression symptoms as measured by HADS were low and the mean values of cancer 
related distress as measured by IES-15 were moderate both before and after genetic 
testing. We also documented a statistically significant decline in the mean levels of 
anxiety symptoms (HADS-A), intrusion (IES-I) and avoidance (IES-A) during the 
follow-up time which also included the dissemination of the BRCA test result. Still, 
around 40% of the patients scored above the cut-off level for anxiety (Paper I, Table 
3), 32% had intrusion scores in the severe range and 24% had avoidance scores in the 
severe range at inclusion (Paper II, Table 2). The proportion of patients with high 
scores on anxiety, intrusion and avoidance symptoms dropped significantly during 
follow-up. Similar results have been shown in other studies on patients with breast or 
ovarian cancer and in individuals undergoing genetic testing for hereditary breast and 
ovarian cancer [85, 104, 126, 128, 177, 178].  
The subgroup of patients with higher levels of anxiety and/or cancer related distress 
needs more attention. A high level of distress has been shown to have a negative 
impact on the patient’s ability to receive and remember information and can lead to 
lower adherence and compliance to treatment and follow-up [179]. This could be of 
potential clinical significance when genetic testing at the time of diagnosis is 
becoming common practice [154, 158, 180]. Patients with higher levels of distress 
may have more difficulties in understanding the consequences of genetic testing. The 
principle of informed consent from the patient is important in all aspects of medical 
practice, including genetic testing. In our study, all patients signed a written consent 
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form for the genetic test, but even so one of the participants expressed in a later focus 
group interview that she could not remember that she had signed any consent [131]. 
This shows that signing a written informed consent not necessarily means that a 
patient is informed, but also raises an opposite concern: what about the patients (52% 
of invited patients in our study) that did not have a genetic test? For some of the 
patients the decision may have been a result of an active choice of not having the 
genetic test, but for others the situation may have been that they were not aware of 
declining a diagnostic genetic test. Those with higher levels of distress are more 
vulnerable for not comprehending the large amount of information received in the 
period immediately after diagnosis [179]. There is a potential that these patients miss 
the testing opportunity if healthcare professionals are not aware of the implication of 
distress and take the necessary time to discuss genetic testing in person with these 
patients [131].  In that aspect, the predictors of increased distress identified in our 
study can be useful to select patients that need more attention.  
Younger patients are more distressed after receiving a cancer diagnosis than the 
elderly; this has been shown in multiple studies including ours (Paper II) [130, 177, 
181]. Genetic testing is especially important in younger patients, because of a higher 
risk of germline pathogenic variants being present - with a potentially higher impact 
on their life expectancy. It would therefore be reasonable to make extra effort in 
assuring that these young patients receive sufficient information to take an active 
choice regarding genetic testing. On the other side, it is reassuring that young patients 
in general are more likely to undergo genetic testing. Both our as well as other studies 
have shown that the acceptance/referral rate for genetic testing is higher among 
younger patients [155, 165, 182].   
Another important predictor of increased distress is shorter time since diagnosis 
(Paper II) [126, 128, 130, 178]. Since the levels of distress decreased quite quickly, 
one could argue that postponing the genetic test only a few weeks could be beneficial. 
However, when the genetic test result is important to guide immediate treatment of 
the patient, postponing is of course not an option, and the present study served as a 
preparation for this situation. For patients where the initial treatment will not differ 
 62 
between carriers and non-carriers of pathogenic germline variants, introducing 
genetic testing at a later stage could be an alternative – especially if the patient has 
high levels of distress or anxiety. 
Many guidelines now recommend genetic testing for all patients with ovarian cancer 
[159, 174, 180]. In our study, patients with ovarian cancer had higher levels of 
distress as compared to patients with breast cancer. These patients could benefit from 
in-person discussion of genetic testing, e.g. with their gynaecologist or oncologist. 
We found that perceived social support, as measured by ISEL [136], was a strong 
predictor of lower levels of both intrusion and avoidance in women undergoing 
genetic testing shortly after a diagnosis of breast or ovarian cancer (Paper II). Some 
researchers equate having a partner and having social support [181], but our study 
indicates that these are two different factors that cannot be used interchangeably. 
While high levels of perceived social support predicted lower levels of intrusion and 
avoidance in our study, we found that women living with a partner had statistically 
significantly higher levels of intrusion symptoms at all three assessment points 
compared to women living alone. We do not have an explanation of this finding in 
our data, and previous research has shown diverging results when it comes to the 
effect of marriage or marriage-like relationship on psychosocial distress in patients 
with cancer [129, 181, 183, 184]. However, the quality of an intimate relationship 
seems to be important [185]. Furthermore, the gender issue must be kept in mind. 
One study found that men with cancer were less likely to develop symptoms of 
psychological distress if they were married, while female cancer patients had lower 
levels of psychological distress if they were not married [186]. The size of the effect 
in our study was modest, and therefore not necessarily clinically relevant. 
Nevertheless, it would be interesting if future studies could confirm whether having a 
cohabitating partner constitutes an extra burden for women newly diagnosed with 
breast or ovarian cancer. If so, the possible reasons should be explored.  
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5.2.3 BRCA variants with reduced penetrance 
In Paper III, we showed that BRCA1 c.5407-25T>A causes aberrant splicing and a 
premature stop codon leading to a truncated BRCA1 protein with loss of the 
important BRCT domain. Furthermore, our results indicated a leakage of normal 
transcript from the variant allele. The biological consequence of a small leakage of 
normal transcript from a spliceogenic DNA variant is not fully known, but this could 
lead to synthesis of functional protein and maintenance of some tumour suppressor 
effect. “Leaky” splice variants are therefore usually classified as VUS [151, 187, 
188]. However, the decreased amount of normal transcript could lead to a reduced, 
although not completely absent, tumour suppressor effect of potential clinical 
significance. In line with this, it is possible that the BRCA1 c.5407-25T>A variant is 
associated with an increased risk of breast and ovarian cancer, but the magnitude of 
risk may be lower than for truncating pathogenic BRCA1 variants. “Leaky” splice 
variants have been described to be disease causing with reduced penetrance for other 
genes [189-191], and this could also be the case for BRCA1 and BRCA2 [151].  
The clinical characteristics of the studied families with BRCA1 c.5407-25T>A were 
consistent with hereditary breast and ovarian cancer of reduced penetrance. The mean 
age of onset of breast or ovarian cancer was 49.9 and 60.4 years, respectively, which 
is lower than reported for the general population (62.2 and 64.8 years, respectively in 
the years 2012-2015) [145], but higher than reported in a large international 
prospective study of clinically ascertained carriers of a BRCA1 pathogenic variant 
(median age of 44 and 54 years, respectively) [53]. However, a population-based 
study found a mean age at diagnosis of 50.3 years in women with a pathogenic 
BRCA1 variant [43]. The mean Manchester score was 16.4 in the 20 families with 
BRCA1 c.5407-25T>A. In the DNA-BONus study (Paper I), the mean Manchester 
score was 8.3 in patients with a negative BRCA genetic test result and 23.3 in patients 
where a truncating pathogenic BRCA variant was found and not previously known in 
the family. Since the Manchester calculations in the BRCA negative patients in the 
DNA-BONus study were based solely on the self-reported structured family history 
collected at inclusion and did not adjust for pathology information, the groups are not 
directly comparable. However, taken together the Manchester scores could indicate 
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an intermediate cancer burden in families with BRCA1 c.5407-25T>A; higher than 
for average patients with breast and ovarian cancer, but lower than for families with 
truncating BRCA variants.  
In the DNA-BONus study, we found BRCA1 c.5407-25T>A in two patients with 
breast cancer. One of the patients was diagnosed through the population 
mammography screening at age 64 years and had two close relatives with ovarian 
cancer after 70 years. The other patient was diagnosed at the age of 47, in a 
surveillance program for BRCA negative familial breast cancer. The breast cancer 
cases were on her mother’s side of the family, while the BRCA1 c.5407-25T>A 
variant was inherited from the father.  
While we were not able to calculate the penetrance of the BRCA1 c.5407-25T>A in 
our small cohort of carriers, this has been done for the BRCA1 missense variant 
c.5096G>A, p.(Arg1699Gln), which we identified in a woman with breast cancer at 
the age of 76 in the DNA-BONus study [192]. The ENIGMA consortium has 
investigated 129 families with p.(Arg1699Gln) and estimated the risk of breast cancer 
by age 70 years to be 20% and the risk of ovarian cancer by age 70 years to be 6% 
[149].  
It is worth noting that three out of the seven breast cancer patients identified with 
pathogenic BRCA variants in the DNA-BONus study had a variant associated with 
(possible) moderate penetrance. As the indications for genetic testing keeps 
broadening, it is likely that more variants with low/moderate penetrance will be 
identified. This is a familiar story in the field of medical genetics: the first patients 
and families that come to attention are those with the most severe phenotype. When 
the genetic cause has been identified, more patients are tested, and often it turns out 
that the phenotype is more variable than first assumed. For several cancer genes it has 
been documented that the penetrance is higher when there is a positive family history 
compared to when the family history is negative [26, 193]. Modifying genetic and 
non-genetic factors play an important role in this variability in penetrance [194, 195].  
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Panel tests where multiple cancer predisposing genes are tested simultaneously are 
now gradually replacing single gene testing in cancer genetics clinics [27, 196]. 
Several of these panels include genes associated with moderate cancer risk and even 
genes where the associated cancer risk has not been sufficiently documented [27, 
197]. The clinical significance of variants in such genes is not as obvious as 
truncating variants in e.g. BRCA1, and the effect is more modifiable by other genetic 
and non-genetic factors. Over time genetic test results have become increasingly 
complex. The picture is no longer “black or white”, which is important to be aware of 
both for doctors ordering genetic tests and for people undergoing testing. When 
moderate penetrant variants are identified in a family, this is in most cases not the 
only contributing factor to the cancer burden in the family and family members 
testing negative for the variant is not necessarily at low risk. Since many of the 
factors contributing to aggregation of cancer in a family are still unknown, and not 
possible to identify by a simple test, the family history retains its value as a picture of 
the total burden of risk in that specific family. Even with easier access to broader 
genetic tests the family history will be important for risk assessment of individuals.  
Furthermore, the complexity of genetic testing and risk assessment understates the 
importance of securing access to genetic competence also in the era of personalised 
medicine and mainstreaming of genetic testing into cancer clinics. Genetics 
professionals should take active part in multidisciplinary teams, to discuss complex 
genetic test results before clinical action is taken on the basis of the result. Patients 
with complex results on diagnostic genetic tests should be referred to post-test face-to 






 In our DNA-BONus study, 45% of patients with breast cancer and 68% of 
patients with ovarian cancer accepted BRCA genetic testing when offered 
shortly after diagnosis (Paper I). 
 We identified a germline pathogenic BRCA variant in a high share (22%) of 
women with ovarian cancer but only in 2% of women with breast cancer 
(Paper I). 
 All carriers of a germline pathogenic BRCA variant fulfilled at least one of the 
Norwegian BRCA test criteria as defined in 2010 (Paper I).  
 Overall the study participants seemed to cope well with the new and simplified 
procedure for diagnostic genetic testing without pre-test genetic counselling. 
There was a statistically significant decline in the mean levels of anxiety 
symptoms (Paper I) and cancer related psychological distress (Paper II) from 
inclusion to six months after dissemination of the BRCA test result. 
 Predictors of increased distress were young age, short time since diagnosis, 
low level of perceived social support, high level of decisional conflict, 
diagnosis of ovarian cancer, and living with a partner (Paper II).  
 The intronic BRCA1 c.5407-25T>A variant that was identified in two 
participants in the DNA-BONus study causes partial skipping of exon 22, and 





7. Future perspectives 
This thesis illustrates the rapid development in the field of clinical cancer genetics. 
The DNA-BONus study served as a preparation for a near future when genetic testing 
would guide treatment decisions in patients newly diagnosed with cancer. This future 
has already entered clinical practice, and new routines for genetic testing and 
counselling of patients with newly diagnosed breast or ovarian cancer have been 
implemented in our health region based on the experiences from this study. At a 
national and international level, Paper I added to the body of knowledge that has led 
to recommendations of genetic BRCA testing for all patients with ovarian cancer. 
Despite increasing access to genetic testing there is still a significant share of eligible 
patients who does not undergo genetic testing, e.g. around half of the patients invited 
in our study. Future studies that investigate why people accept or decline genetic 
testing would be helpful for the planning of new routines for diagnostic genetic 
testing of patients with cancer.  
The criteria for genetic testing continue to broaden, and eventually this could lead to 
a practice where genetic testing is becoming available for all patients with specific 
forms of cancer. A further expansion of the access to genetic testing is not unlikely, 
e.g. to patients with all forms of cancer, and ultimately to everyone through direct-to-
consumer genetic testing and population screening. Future studies should focus on 
evaluation of different levels of genetic information and counselling. New effective 
ways of delivering genetic information to large target groups are needed, at the same 
time as access to genetic counselling must be ensured for subgroups in need of extra 
intervention. Studies that explore the experiences of individuals identified with 
pathogenic BRCA variants through these new models of genetic testing would be of 
interest.  
As elaborated in Paper III, the classification of BRCA sequence variants is 
challenging and extremely important for proper clinical management of patients 
carrying these variants. For “leaky” splice variants the ultimate goal would be to find 
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a correlation between the amount of normal transcript produced by the variant allele 
and the magnitude of cancer risk. National and international collaboration and sharing 
of sequence and functional data should be a priority for diagnostic genetic 
laboratories, researchers and authorities.  
Several of these aspects will be addressed in ongoing and future research projects at 
the Western Norway Familial Cancer Center. We will study the use of chatbot 
technology as a communication tool to support individuals undergoing genetic testing 
for hereditary breast and ovarian cancer. In another study, we will determine the 
prospective cancer risk in families with suspected hereditary cancer, but where 
pathogenic variants in high risk cancer genes have not been identified. Finally, we 
have initiated a national collaborative study to reveal discrepancies in interpretation 
of BRCA1 sequence variants in Norway.  
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BRCA1/2 testing in newly diagnosed breast and ovarian
cancer patients without prior genetic counselling: the
DNA-BONus study
Hildegunn Høberg-Vetti*,1,2, Cathrine Bjorvatn1,2,3, Bent E Fiane4, Turid Aas5, Kathrine Woie6, Helge Espelid7,
Tone Rusken8, Hans Petter Eikesdal3,9, Wenche Listøl1,2, Marianne T Haavind1, Per M Knappskog2,3,
Bjørn Ivar Haukanes2, Vidar M Steen1,2,3,11 and Nicoline Hoogerbrugge1,10,11
Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the result affects both treatment and
cancer prevention in patients and relatives. Through the DNA-BONus study we offered BRCA1/2 testing and familial risk
assessment to all new patients with breast (N=893) or ovarian (N=122) cancer diagnosed between September 2012 and April
2015, irrespective of family history or age, and without prior face-to-face genetic counselling. BRCA1/2 testing was accepted by
405 (45.4%) and 83 (68.0%) of the patients with breast or ovarian cancer, respectively. A pathogenic BRCA1/2 variant was
found in 7 (1.7%) of the breast cancer patients and 19 (22.3%) of the ovarian cancer patients. In retrospect, all BRCA1/2
mutation carriers appeared to fulfill current criteria for BRCA1/2 testing. Hospital Anxiety and Depression Scale (HADS) scores
showed that the mean levels of anxiety and depression were comparable to those reported for breast and gynecological cancer
patients in general, with a significant drop in anxiety symptoms during a 6-month follow-up period, during which the test result
was forwarded to the patients. These results show that BRCA1/2 testing is well accepted in newly diagnosed breast and ovarian
cancer patients. Current test criteria based on age and family history are sufficient to identify most BRCA1/2 mutation carriers
among breast cancer patients. We recommend germline BRCA1/2 testing in all patients with epithelial ovarian cancer because of
the high prevalence of pathogenic BRCA1/2 variants.
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INTRODUCTION
Breast cancer is by far the most common cancer in women worldwide,
with more than 1.6 million new cases diagnosed each year. Ovarian
cancer is substantially less common, with ∼ 240 000 new cases each
year, but with higher mortality.1 Most cases of breast and ovarian
cancer are sporadic, but a minor fraction (2–8% and 8–15%,
respectively) is caused by inheritance of pathogenic germline variants
in BRCA1 or BRCA2, with variation in prevalence and relative
contribution of BRCA1 and BRCA2 in different populations.2–8 It is
important to identify these patients because the presence of such
germline variants affects treatment, follow-up and further cancer
prevention in patients with breast or ovarian cancer.9,10 In addition, it
may strongly influence upon their close relatives, as BRCA1/2 testing
can identify healthy BRCA1/2 mutation carriers at high risk and
thereby prevent cancer and cancer-related deaths through increased
surveillance and prophylactic surgery.10–16
The most common current practice of BRCA1/2 testing is based on
referral of suspected high-risk patients to clinical genetics services for
specialized face-to-face genetic counselling. This procedure tradition-
ally includes collection and confirmation of family history, risk
assessment and eventually BRCA1/2 testing followed by a post-test
counselling with dissemination of test results and advice concerning
surveillance and follow-up.17–19 Based on family history, BRCA1/2-
negative families with increased risk of familial breast cancer can also
be identified.18,20
However, this traditional approach is time consuming and resource
demanding for both the patient and the health-care system, with an
inherent risk of focusing too much on healthy relatives and not
reaching all the cancer patients in question. Moreover, the discovery
that BRCA1/2 status can inform treatment decisions in breast and
ovarian cancer patients has led to an increased demand for BRCA1/2
testing at the time of cancer diagnosis.9,21 New approaches to
BRCA1/2 testing and genetic counselling may be needed to meet this
situation. The aim of this project was therefore to assess the feasibility
and impact of offering BRCA1/2 testing to all newly diagnosed patients
with breast or ovarian cancer without prior face-to-face genetic
counselling. We here report the uptake of BRCA1/2 testing, the
incidence of pathogenic BRCA1/2 variants and the individual risk
profiles among these unselected breast and ovarian cancer patients.
As the psychosocial impact of such BRCA1/2 testing in newly
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diagnosed cancer patients without prior genetic counselling is scarcely
described,22 we also examined the symptoms of anxiety and depres-
sion at inclusion and during the follow-up period of 6 months.
PATIENTS AND METHODS
Recruitment of patients
The patients were recruited from four hospitals in Western Norway (Haukeland
University Hospital, Stavanger University Hospital, Haugesund Hospital and
Førde Central Hospital), including three surgical departments and two
gynecological departments, from September 2012 to April 2015. All patients
with newly diagnosed breast or ovarian cancer were invited to participate in the
study (for overview, see Figure 1). The patients received written information on
the project and general information on hereditary breast and ovarian cancer,
including the mode of inheritance and the potential consequences of a positive
test results; such as the elevated cancer risk, recommended follow-up and risk-
reducing strategies for the patient and healthy relatives. They were also
informed that a positive test result could affect the surgical treatment of breast
cancer patients, whereas specific information on novel therapies, like PARP-
inhibitors, was not given. In addition, the patients had the opportunity to
contact a genetic counselor on telephone for any further questions. All
participants signed informed consent and filled in a structured questionnaire
on personal and family medical history. The patients could choose BRCA1/2
testing with or without participating in an associated study of psychosocial
aspects (see below). A blood sample was then collected at the local hospital and
sent to a central laboratory for BRCA1/2 analysis. The study protocol was
approved by the Regional Committee for Medical and Health Research Ethics
(reference number REK Vest 2012-60).
DNA isolation, BRCA mutation analysis and clinical assessments
Genomic DNA was purified from EDTA-anticoagulated blood using the
QiaSymphony instrument (Qiagen, Hilden, Germany). Genotyping of a panel
of 20 pathogenic BRCA1 and 10 pathogenic BRCA2 variants that are recurrent
in the Norwegian population was carried out using TaqMan Low-Density
Arrays on the ABI 9700 instrument (Applied Biosystems, Foster City, CA, USA)
as recommended by the manufacturer. An overview over the variants and
sequences for the corresponding primers and probes is given in the
Supplementary Table 1. In addition, the BRCA1 and BRCA2 genes were
analyzed for deletions and insertions by Multiplex Ligation-dependent Probe
Amplification (MLPA) technology (P002 BRCA1 and P045 BRCA2 MLPA
probe mixes; MRC-Holland, Amsterdam, The Netherlands).
The result of the BRCA1/2 testing was given to the patient by a genetic
counselor within 3 weeks after blood sample collection (Figure 1). In addition,
the result was reported to the clinician who was responsible for treating the
patient, to be filed in the patient’s medical record at the hospital. If the test
result was negative and there was no increased familial cancer risk, the patient
received the result by letter. Patients with a positive test result or with a
personal or family history indicative of a high risk of hereditary cancer were
contacted over the phone by a genetic counselor and were offered traditional
face-to-face genetic counselling and further investigations in one of our
outpatient clinics.
Based on collection of family history and confirmation of cancer diagnoses in
relatives, selected patients were then offered extended genetic testing, with
Sanger sequencing of all exons and flanking intron sequence in both BRCA1
and BRCA2. We used the following reference sequences: BRCA1: NG_005905.2
(gene), NM_007294.3 (mRNA), NP_009225.1 (protein); BRCA2: NG_012772.3
(gene), NM_000059.3 (mRNA) and NP_000050.2 (protein)).
To classify the sequence variants we followed the recommendations given by
the International Agency for Research on Cancer (IARC).23 Pathogenic (class 5)
and likely pathogenic (class 4) variants were regarded as positive genetic test
results and have been submitted to the Leiden Open Variation Database
(LOVD 3.0 shared installation; www.databases.lovd.nl/shared/genes). In this
article we use the term BRCA1/2 mutation carrier for patients in whom a
pathogenic or likely pathogenic variant was found.
All patients were categorized before BRCA1/2 testing depending on the
presence of increased familial cancer risk or not. Increased risk was defined as
personal at risk cancer history (eg, patients with young age at diagnosis, bilateral
breast cancer or both breast and ovarian cancer) or positive family history
(eg, close relative with breast cancer before 50 years of age or ovarian cancer at
any age, two or more relatives with breast cancer or both breast and ovarian
cancer in relatives) or a combination of personal at risk cancer history and
positive family history, according to the current national clinical criteria for
BRCA1/2 testing (see also legend to Table 1). The participants were in addition
rated by the Manchester scoring system for BRCA1/2 testing.24,25
Psychological measurements
Participants who gave informed consent for the psychosocial part of the project
were asked to fill in questionnaires at baseline when they were offered genetic
testing (T1), at 1 week after disclosure of the BRCA1/2 test result (T2) and
6 months after disclosure of the BRCA1/2 test result (T3). In the present study,
we have used data from the Hospital Anxiety and Depression Scale (HADS).26
HADS comprises two subscales for symptoms of anxiety and depression,
respectively, each with 7 items to be scored on a 4-point (0–3) scale, giving a
range of subscores from 0 to 21. The reliability of the HADS subscales in this
study, as estimated with Cronbach’s α, had a range of 0.83–0.88 for HADS
anxiety and 0.80–0.86 for HADS depression at the three assessments. Subscale
scores of ≥ 8 were used as cutoff for defining higher, caseness-relevant levels of
anxiety and depression.27
Statistical methods
Descriptive statistics were used for psychological and clinical variables,
reporting the mean values, SD and range. To analyze the changes over time
in HADS anxiety and depression scores, we used a paired sample t-test and
McNemar’s exact test. Independent sample t-test was used to compare the
means of two independent groups and χ2 test was used to analyze dichotomous
variables for independent groups.
Missing values were replaced by the individual’s own average score for HADS
if 60% or more of the items were filled in by the respondents. All statistical





Patient receives a phone call from a
genetic counselor and is invited for
genetic counselling and/or
further genetic testing
Patient is informed of
the result by a
letter from the
genetic counselor
All newly diagnosed patients
with breast or ovarian cancer
Normal test result
Personal or family history indicating






Blood sampling at the
clinical department
Analysis result report is sent to
the genetic department
The patient’s physician receives
a copy of the result report
Figure 1 Flowchart showing the inclusion of patients and reporting of results
in the DNA-BONus study.
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analyses were performed using IBM SPSS Statistics for Windows, Version 22.0
(Armonk, NY, USA).
RESULTS
A total of 1015 patients with either breast cancer (N= 893) or ovarian
cancer (N= 122) were offered BRCA1/2 testing at the time of cancer
diagnosis, of whom 405 (45.4%) of the breast cancer patients and 83
(68.0%) of the ovarian cancer patients completed the genetic testing.
The mean age of the participants was 56.9 years (SD 12.4, range
(min–max) 23–89) in the patients with breast cancer and 60.5 years
(SD 11.9, range 24–88) in the patients with ovarian cancer (Table 1).
Among the participants, 202 (49.9%) of the patients with breast cancer
and 70 (84.3%) of the patients with ovarian cancer were eligible for
BRCA1/2 testing according to current national clinical guidelines
(Table 1). The median time from diagnosis to blood sampling was
34 days (mean 68, range 0–1402) and the median time from diagnosis
to the patient received initial test result was 52 days (mean 87, range
12–1423) (data not shown). For 13 patients, the interval between
diagnosis and blood sampling exceeded 1 year.
A pathogenic BRCA1/2 variant was identified in 7 (1.7%) of the 405
breast cancer patients (mean age of 50.6 (SD 15.8, range 32–76) years;
Table 1), of whom 6 carried a BRCA1 and 1 a BRCA2 pathogenic
variant (Table 2). Three BRCA1 and one BRCA2mutation carriers had
a breast cancer that was triple negative (Er-/Pr-/HER2-) and all seven
breast cancers were HER2 negative (Table 2). Interestingly, as many as
19 (22.3%) of the 83 ovarian cancer patients (mean age 56.5 (SD 9.1,
range 44–72) years) were BRCA1/2 mutation carriers (Table 1),
including 15 with a pathogenic BRCA1 variant and 4 patients with a
pathogenic BRCA2 variant (Table 2). Most ovarian cancers were
serous carcinomas, apart from one poorly differentiated carcinoma
and one endometroid adenocarcinoma. The majority of the mutation
carriers (N= 21; 80.8%) were identified by the standard test panel of
recurrent mutations (Table 2), where 3 of the most frequent
Norwegian pathogenic founder variants in BRCA1 (c.1556del,
c.697_698del and c.3228_3229del) were detected in 15 (57.7%) of
the mutation carriers. Four additional pathogenic variants were
identified by Sanger sequencing of selected breast cancer (N= 94) or
ovarian cancer (N= 31) patients with a particularly high risk of
carrying a pathogenic BRCA1/2 variant, based on the personal and
family history (see Table 2). During the first (years 2012–2013) and
second (years 2014–2015) half of the DNA-BONus study period,
26.1% (55 out of 211) and 25.3% (70 out of 277) of the participants
were selected for Sanger sequencing, respectively. Out of the total
population of 488 patients, no one had BRCA1/2 alterations that could
be detected by MLPA.
Among the 272 patients fulfilling the current national criteria for
diagnostic BRCA1/2 testing at inclusion, 6 out of 202 breast cancer
patients (3.0%) and 18 out of 70 ovarian cancer patients (25.7%) were
found to be mutation carriers (Table 1). Among 216 patients not
meeting current clinical test criteria at inclusion, the corresponding
numbers of BRCA1/2 mutation carriers were 1 of the 203 breast
cancer patients (0.5%) and 1 of the 13 ovarian cancer patients (7.7%).
However, it should be noted that the breast cancer patient with a
pathogenic BRCA1 variant and the ovarian cancer patient with a
pathogenic BRCA2 variant, who apparently had negative family
histories upon inclusion, were both subsequently reclassified as having
familial risk, based on extended pedigrees obtained through the
genetic counselling (see below, Discussion section).
The mean combined Manchester score at inclusion was 8.9 (range
2–71) (data not shown), with 67 out of 488 patients (13.7%) having a
score of ≥ 15 (Table 1). A pathogenic BRCA1/2 variant was found in
13 out of 67 patients (19.4%) with a score of ≥ 15 and in 13 out of 421
patients (3.1%) with a score o15 (Table 1; summarized numbers).
Among the 26 BRCA1/2 mutation carriers, the mean combined
Manchester score at inclusion was 19.5 (range 4–71) (Table 2;
summarized numbers). After genetic counselling and collection of
additional clinical information, including pathology reports, the scores
could be recalculated for 25 of the 26 mutation carriers (Table 2). The
mean combined score increased to 27.7 (range 14–81) (data not
shown), with 24 mutation carriers having a score of ≥ 15, whereas the
remaining mutation carrier had a score of 14 (Table 2).
All 26 BRCA1/2 mutation carriers accepted the offer of traditional
face-to-face post-test genetic counselling. Among participants with a
negative result on the initial BRCA1/2 panel and MLPA analysis,
genetic counselling was offered for 188 patients (40.3% of total) with a
personal at risk cancer history indicating further genetic testing
(eg, young age at diagnosis or more than one primary cancer) or
with a positive family history indicative of either familial breast cancer
(eg, two or more breast cancer cases in first-degree relatives) or
another hereditary cancer syndrome. The acceptance rate for genetic
counselling in this group was 93.6% (N= 176).
Because of the potential risk of imposing additional psychosocial
burden by offering and performing BRCA1/2 testing in the newly
diagnosed cancer patients, we measured the level of anxiety and
depression scores before testing and at 1 week and 6 months after
disclosure of the test result in a subset of participants (Table 3).
Among these 215 patients, the median time from diagnosis to blood
sampling was 32 days (mean 56, range 0–436) and median time from
diagnosis to received result was 50 days (mean 75, range 12–456) (data
not shown). The mean HADS subscale score for anxiety symptoms
was 6.84 (SD 4.28) at baseline (ie, time of inclusion), with a significant
decrease to 4.88 (SD 3.86) 6 months after disclosure of the BRCA1/2
test result (Po0.001). The percentage of patients with higher levels of
anxiety symptoms, defined as scores ≥ 8, decreased significantly from
inclusion (39.9%) to 1 week (23.6%, Po0.001) and 6 months (19.8%,
Po0.001) after disclosure of the test result, respectively. During the
observation period there was no significant change in depression
symptoms, with a mean HADS score of 3.32 (SD 3.07) at baseline and
2.65 (SD 3.04) at 6 months. Approximately 10% of the patients
showed higher levels of depression symptoms with a score of ≥ 8, both
at baseline and follow-up measurements (Table 3). There were no
significant differences in HADS scores between patients with breast
(N= 138) and ovarian (N= 29) cancer, or between mutation carriers
(N= 8) and noncarriers (N= 159) (data not shown).
To explore the effect of time after diagnosis on the HADS scores, we
divided the sample in two groups, with N= 171 (83.0%) having less
than and N= 35 (17.0%) having more than 90 days from cancer
diagnosis to blood sampling. There were no significant differences in
HADS scores between the two groups (data not shown).
Compared with the participants who only agreed to genetic testing
(mean age 61.6 years), the patients who also took part in the
psychosocial study were significantly younger (Po 0.001), with a
mean age of 56.2 years (data not shown). There were no significant
differences between the two groups regarding educational level or type
of cancer diagnosis (breast or ovarian).
DISCUSSION
The main findings in this study are that: (1) most patients with newly
diagnosed ovarian cancer accept germline BRCA1/2 testing, with
significantly lower uptake among breast cancer patients; (2) there is
a high prevalence of BRCA1/2 mutation carriers in the group of
ovarian cancer patients; (3) all patients who were identified with a
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pathogenic BRCA1/2 variant fulfill our current clinical criteria for
diagnostic BRCA1/2 testing; and (4) the level of anxiety and depression
symptoms in the participants at inclusion was comparable to what can
be found in cancer patients in general.28,29
Ovarian and breast cancer patients with pathogenic BRCA1/2
variants are candidates for targeted drug therapy, such as PARP
inhibitors.21 Recently, the US Food and Drug Administration (FDA)
approved a PARP inhibitor for use in ovarian cancer (http://www.fda.
gov/newsevents/newsroom/pressannouncements/ucm427554.htm).
Our study shows that, even before such treatment options became
available, BRCA1/2 testing was well accepted among newly diagnosed
patients, with 68% participation rate among the women with ovarian
cancer, whereas 45% of patients with breast cancer chose to undergo
BRCA1/2 testing. There may be a selection bias among the participants
because, on average, patients with breast cancer and ovarian cancer in
our study were younger (mean age 56.9 and 60.5 years, respectively) as
compared with patients with these cancers in the Norwegian popula-
tion in general. According to national numbers, the mean age of all
cases with breast cancer and ovarian cancer diagnosed between 2008
and –2012 was 61.5 and 65.4 years, respectively,30 thereby indicating
that older patients may have declined participation in our study. This
could be particularly relevant for breast cancer patients with low
a priori risk of carrying a pathogenic BRCA1/2 variant. The assump-
tion of a certain degree of risk-based selection in the uptake is further
supported by the fact that among the participants, 50% of the patients
with breast cancer and 480% of the patients with ovarian cancer were
eligible for diagnostic BRCA1/2 testing according to the current
clinical guidelines. For obvious reasons the uptake will be higher
when the result of BRCA1/2 testing influences treatment options.21
In total, we identified 26 patients with a pathogenic BRCA1/2
variant and by that identified 22 new BRCA1/2 families. This finding
supports a need for increased availability and use of such BRCA1/2
testing, as a supplement to the existing referral systems and service in
cancer genetics. Our study also reports a high prevalence (22.3%) of
pathogenic BRCA1/2 variants in ovarian cancer patients, substantially
higher than reported by others.3–5 This may be caused by a high
prevalence of pathogenic founder variants in our population, but
surprisingly the prevalence among patients with breast cancer is rather
low (1.7%) compared with international data.2,6 The highest pre-
valence of BRCA1/2 mutation carriers has been reported in popula-
tions with very strong founder effects, and most studies on the
frequency of pathogenic BRCA1/2 variants in patients with sporadic
breast cancer have had some form of selection criteria, for example,
young age at onset or triple-negative histology.2,7,8 In the DNA-
BONus study, we offered genetic testing to all patients with newly
diagnosed breast cancer that, in combination with a rather low
prevalence of pathogenic BRCA2 variants in the Norwegian
population,6 at least in part may explain the rather low frequency of
pathogenic BRCA1/2 variants among our patients with breast cancer.
At inclusion, all but two of the 26 BRCA1/2 mutation carriers
fulfilled the current clinical recommendations for diagnostic BRCA1/2
testing in Norway. One patient with breast cancer after the age of 75
years apparently had a negative family history according to the
information forwarded at inclusion. However, further examination
revealed that her sister died from ovarian cancer before the age of 50
years. The other patient was a woman with ovarian cancer after the age
of 70 years. We were informed at inclusion that she had two first-
degree relatives with abdominal cancer and cervical cancer, respec-
tively, both after the age of 70 years. During the genetic counselling
these diagnoses were both confirmed to be ovarian cancer cases.
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criteria for diagnostic BRCA1/2 testing when a proper personal and
family history had been taken.
The Manchester scoring system is a frequently used tool to identify
individuals and families at high risk of having a pathogenic BRCA1/2
variant.24 In this study, we found that the Manchester scores obtained at
inclusion were markedly lower than the real values (see below). In
retrospect, all BRCA1/2 mutation carriers had combined Manchester
scores at ≥ 14 points, demonstrating that the hereditary breast and
ovarian cancer families identified through testing of patients with inci-
dental breast or ovarian cancer do not differ significantly from families
identified through the traditional route. These findings indicate that
most BRCA1/2 mutation carriers can be identified through evidence-
based clinical criteria, also within a group of incidental patients.
In order to identify patients at risk of non-BRCA1/2 familial breast
cancer and other causes of hereditary cancer, we systematically
collected structured family history from the participants before
BRCA1/2 testing and employed a low threshold for our genetic
counselors to contact the participants for additional information.
Indeed, the importance of family history should not be neglected when
the availability of BRCA1/2 testing increases and more patients with
breast cancer are tested in routine clinical practice. Most familial
breast cancer risk is not caused by pathogenic BRCA1/2 variants, and
women belonging to BRCA1/2-negative breast cancer families are also
at increased risk for breast cancer.20 The importance of obtaining a
structured family history was illustrated by the fact that BRCA1/2
mutation carriers in our study scored significantly higher in the
Manchester scoring system when taking into account the information
collected during the genetic counselling procedure, as compared with
the rating based on the initial self-reported information. In this regard,
oncologists and surgeons may need additional support and training to
extract a structured and relevant family history.31,32
The traditional genetic counselling procedure has obvious benefits
with respect to high-quality family history collection, and it has been
shown to increase cancer-related knowledge and decrease distress in
newly diagnosed cancer patients with an elevated risk of hereditary
cancer.33 However, because this procedure is resource demanding,
alternative approaches are needed when treatment-driven genetic
testing is offered to larger patient groups with lower probability of
carrying a pathogenic BRCA1/2 variant. Written, telephone-based or
digital information provided by a clinical geneticist or genetic
counselor, together with adequate information from the oncologist
or surgeon, could be considered as an alternative for some patients.22
Patients at increased risk of psychosocial distress should have easy
access to genetic counselling. An open telephone line to a genetic
counselor might not be optimal for patients newly diagnosed with
cancer, as we experienced that o20 patients actually contacted the
genetic counselor for more information before testing throughout the
whole DNA-BONus study period of two-and-a-half years. In order to
discuss the consequences of the BRCA1/2 test results for the patient
and other family members, as well as to explain complex test results
and other hereditary causes of cancer, we also advise genetic
counselling in case of a positive BRCA1/2 test result and in case of a
personal or family history suggestive of hereditary cancer.
As the most common current practice of BRCA1/2 testing is based
on referral of selected high-risk subjects to extensive face-to-face
procedures of genetic counselling before BRCA1/2 testing,17,18 we
investigated whether our new simplified approach could lead to
increased anxiety or depression in the newly diagnosed patients.
Interestingly, the level of anxiety symptoms was comparable to those
reported for patients with breast cancer and gynecological cancer in
general,28,29 but higher than normal population values.34 Approxi-
mately 40% of the patients had a HADS subscale score above the
defined threshold for symptoms of anxiety27 at inclusion, and the level
of anxiety decreased significantly during the 6-month follow-up period
that also included the dissemination of the BRCA1/2 test result. The
drop in the level of anxiety symptoms during the observation period
may simply reflect the adjustment to the cancer diagnosis and
treatment, and genetic testing in our study did not appear to influence
on this expected drop.
There are some limitations to our study. Because of ethical
regulations, we had no information about the patients who declined
participation in the study. Another limitation is that Sanger sequen-
cing of the BRCA1/2 genes was only performed on selected high-risk
patients, implying that some of the lower-risk patients could be
carriers of rare BRCA1/2 variants that were not covered by the
BRCA1/2 panel test. In this respect, it should be noted that the
methods and two-step procedure for BRCA1/2 testing (ie, multiplex
panel test for recurrent variants, plus optional BRCA1 plus BRCA2
Table 3 HADS anxiety and depression subscale scores at various time points for a subset of DNA-BONus participants
At inclusion
One week after disclosure
of genetic test result
Six months after disclosure
of genetic test result
(T1) (T2) (T3)
HADS anxiety
No. of patients 213 191 167
Subscore mean (SD) 6.84 (4.28) 5.29a (4.06) 4.88b (3.86)
Score ≥8 (%) 39.9 23.6c 19.8d
HADS depression
No. of patients 215 190 169
Subscore mean (SD) 3.32 (3.07) 2.90e (3.30) 2.65f (3.04)
Score ≥8 (%) 10.2 10.0 g 10.7h
Abbreviation: HADS, Hospital Anxiety and Depression Scale.
aT1 vs T2: Po0.001.
bT1 vs T3: Po0.001; paired sample t-test.
cT1 vs T2: Po0.001.
dT1 vs T3 Po0.001; McNemar’s exact test.
eT1 vs T2: P=0.32.
fT1 vs T3: P=0.11; paired sample t-test.
gT1 vs T2: P=1.00.
hT1 vs T3: P=0.42; McNemar’s exact test.
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Sanger sequencing) remained unchanged during the whole inclusion
period, and that the fraction of patients who were sequenced was
almost the same in the first and second half of the DNA-BONus study.
Another potential weakness is that patients with previously known
pathogenic BRCA1/2 variants, who were diagnosed with cancer during
the DNA-BONus study period, might have declined participation
because of low relevance, thereby reducing the total count of BRCA1/2
mutation carriers among the participants. Finally, some of the psycho-
social results are limited by a small number of participating BRCA1/2
mutation carriers and should therefore be interpreted with caution.
In conclusion, we show that BRCA1/2 mutation testing is well
accepted among patients with newly diagnosed breast or ovarian
cancer. We further conclude that current clinical guidelines are
sufficient to identify the majority of the BRCA1/2 mutation carriers
among patients with breast cancer. Because of the high prevalence of
pathogenic BRCA1/2 variants, we recommend that all patients with
epithelial ovarian cancer are offered germline BRCA1/2 testing,
irrespective of age or family history of cancer.
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A. Information sheet 
B. Request form 
    Regionalt kompetansesenter for arvelig kreft  
 
Besøksadresse: Haukeland Universitetssykehus, Jonas Liesvei 65,  
Postadresse: Helse Bergen HF, Postboks 1, 5021 Bergen  
Telefon 55 97 54 75  Telefaks 55 97 54 79, E-post: rkak@helse-bergen.no 
Besøk vår internettside http://www.helse-bergen.no/arveligkreft 
 
Delstudie 1: Vurdering av risiko for arvelig bryst- og eggstokkreft basert på familiehistorie og 
DNA-testing av pasienter med bryst- og/eller eggstokkreft i Norge 
Delstudie 2: Psykososiale aspekter ved genetisk testing av pasienter som behandles for brystkreft 
eller eggstokkreft 
 
Bakgrunn og hensikt 
Ca 2 % av alle tilfeller av brystkreft og ca 10% av alle tilfeller av eggstokkreft kan skyldes en nedarvet 
genfeil i BRCA1- eller BRCA2-genet. Denne studien er todelt. Delstudie 1 vil bidra til å kartlegge 
forekomsten av slike genfeil i Norge ved å tilby gentest til alle pasienter som er under behandling for 
bryst- eller eggstokkreft. Gjennom innhenting av opplysninger om krefttilfeller i deltakernes familier vil 
den også gi en oversikt over det totale behovet for genetisk utredning og veiledning av pasienter med 
bryst- eller eggstokkreft. Prøver samlet inn i denne studien vil også utgjøre et viktig grunnlag for søk etter 
andre genetiske forhold som kan tenkes å bidra til kreftutvikling. I delstudie 2 ønsker vi å undersøke 
hvordan personer som har kreft opplever å få tilbud om en gentest, og evt måtte forholde seg til en arvelig 
risiko for kreft for seg og familien. Dette for at vi skal kunne bedre planlegge fremtidig ivaretakelse av 
personer som gjennomfører gentester, for eksempel i forhold til hvilken informasjon de trenger og når 
denne informasjonen er mest gunstig å gi. Regionalt kompetansesenter for arvelig kreft, Helse Vest, er 
ansvarlig for begge disse delstudiene. 
 
Hva innebærer studien? 
Du kan velge å delta enten i begge delstudiene, bare i delstudie 1, eller bare delstudie 2. Pasienter med økt 
risiko for arvelig kreft, og som oppfyller kriterier fastsatt av Helsedirektoratet, har mulighet for å velge 
genetisk testing og utredning uten å delta i forskning.  
 
Delstudie 1:  
a)         Dersom du velger å delta i studie 1, vil du bli testet for vanlige genfeil i BRCA1- og BRCA2- 
om egen sykdom og kreftsykdommer i familien. Du vil selv få informasjon om resultatet av gentesten etter 
2-4 uker. Resultatet vil også bli formidlet til behandlende lege. Hvis du får påvist genfeil, eller andre 
forhold gir grunnlag for videre genetisk utredning (slik som flere tilfeller av kreft i familien), vil du få 
tilbud om genetisk veiledning.  
b) Avidentifiserte prøver fra delstudie 1 vil etter at BRCA-gentesten er utført inngå i en 
forskningsbiobank og kan bli brukt til å kartlegge andre genetiske faktorer som kan være 
forbundet med kreftutvikling.  
Appendix 1 A. Information sheet
 
Delstudie 2: 
Hvis du velger å delta i delstudie 2, må du fylle ut ett spørreskjema før gentesten, ett rett etter gentestsvaret 
er formidlet og ett ca 6 måneder etter gentest. Det vil ta ca 20 min å fylle ut spørreskjemaene. 
 
Mulige fordeler og ulemper 
Det å få påvist en genfeil, som medfører høy risiko for kreft, kan oppleves som en ekstra belastning i en 
fase hvor man er under behandling for en alvorlig kreftsykdom. Dette medfører nye valgsituasjoner med 
hensyn på risikoreduserende tiltak, og en visshet om at ens familiemedlemmer også kan ha høy risiko for å 
få kreft. Fordelen med å vite om at man har en genfeil kan på den annen side være at man dermed får en 
forklaring på hvorfor man ble syk, evt. også hvorfor mange i familien er rammet av kreft. For noen kan 
muligheten for å gjøre risikoreduserende tiltak (se kapittel B) med hensyn på ny kreftsykdom også være en 
stor fordel. Dersom en genfeil påvises kan nære familiemedlemmer, slik som døtre og søstre, i tillegg få 
tilbud om adekvat oppfølging. Vi ser også at noen av spørsmålene i delstudie 2 kanskje kan minne deg på 
ting du synes er vanskelig å tenke på. Dersom disse spørsmålene skulle bekymre deg eller det er andre 
forhold ved spørreskjemaene du vil diskutere er du hjertelig velkommen til å ta kontakt med oss, se 
kontaktinfo under. 
 
Hva skjer med prøvene og informasjonen om deg?  
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Resultatet av gentesten blir lagret i prøvedatabasen og pasientjournalen ved Senter 
for medisinsk genetikk og molekylærmedisin og i din journal ved sykehuset der du blir behandlet for 
kreftsykdommen. I tillegg til informasjonen som du selv oppgir i spørreskjemaene, vil vi innhente 
supplerende informasjon fra din sykejournal ved sykehuset der du blir behandlet for kreftsykdommen. Det 
kan også bli innhentet informasjon om deg fra Kreftregisteret. Denne informasjonen, og informasjonen 
som du selv oppgir i rekvisisjonsskjemaet (delstudie 1) og evt spørreskjemaene (delstudie 2) vil bli 
oppbevart avidentifisert på forskningsserveren ved Haukeland Universitetssykehus.  
Prøvene vil bli lagret avidentifisert i en forskningsbiobank ved Regionalt kompetansesenter for arvelig 
kreft, og vil kunne bli brukt til å identifisere andre genetiske faktorer av betydning for kreftuvikling (se 




Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke til å 
delta i studien. Dersom du ønsker å delta, undertegner du den/de aktuelle samtykkeerklæring(ene) på siste 
side. Om du nå sier ja til å delta, kan du senere trekke tilbake ditt samtykke uten at det påvirker din øvrige 
behandling. Dersom du senere ønsker å trekke deg, kan du kontakte overlege Hildegunn Høberg Vetti 







Hvis du ønsker å snakke med en genetisk veileder for å få mer informasjon om hva gentesten går ut på, 
eller du har andre spørsmål i forhold til arvelig kreft eller denne studien, kan du ringe vår kontakttelefon, 
tlf nr 55 97 54 75  
Du er også velkommen til å ta kontakt på e-post: rkak@helse-bergen.no 
 
Ytterligere informasjon om studien finnes i kapittel A  utdypende forklaring av hva studien 
innebærer. 
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B  Personvern, 
biobank, økonomi og forsikring.  
Samtykkeerklæring følger etter kapittel B. 
 
 
Med vennlig hilsen 
 
             
Hildegunn Høberg Vetti    Cathrine Bjorvatn 
Overlege      Genetisk veileder, PhD 























Kapittel A- utdypende forklaring av hva studien innebærer 
Bakgrunn og hensikt 
De fleste tilfeller av kreft er ikke arvelig betinget, men i ca 5-10 % av tilfellene er arv trolig en viktig 
årsaksfaktor. Ca 2 % av alle tilfeller av brystkreft og ca 10% av alle tilfeller av eggstokkreft kan skyldes en 
nedarvet genfeil i ett av de to genene som kalles BRCA1 eller BRCA2, men dette tallet er usikkert og 
varierer mye fra populasjon til populasjon. I Norge har gentesting i mange år vært tilbudt familier med høy 
forekomst av brystkreft og/eller eggstokkreft. Men det viser seg at slik testing basert på familiehistorie 
ikke er egnet til å fange opp alle pasienter som har en arvelig form for brystkreft eller eggstokkreft. Denne 
studien er todelt. 
Delstudie 1 vil bidra til å kartlegge forekomsten av slike genfeil i Norge, og vil trolig føre til at flere 
personer med genfeil i BRCA1- eller BRCA2-genet blir identifisert. I tillegg vil den identifisere pasienter 
med en familiær form for hhv brystkreft eller eggstokkreft, men hvor dette ikke skyldes genfeil i BRCA1- 
eller BRCA2-genet. Vi vil også se nærmere på pasientene som får påvist genfeil og deres familier, og 
sammenligne disse med familier som er identifisert gjennom tradisjonell medisinsk genetisk utredning. 
Det vil også være aktuelt å forsøke å identifisere andre genetiske forhold som påvirker kreftrisiko og 
kreftutvikling.  
Delstudie 2: Hovedmålet i denne delstudien er å kartlegge de psykososiale aspekter ved genetisk testing 
av alle pasienter som er under behandling for bryst- eller eggstokkreft. Vi ønsker å undersøke hvordan 
genetisk informasjon kan gis best mulig innenfor en vanlig klinisk hverdag. Det foreligger per i dag ingen 
publiserte forskningsartikler som omhandler psykososiale aspekter ved gentesting av denne gruppen 
pasienter. Genetisk informasjon skiller seg fra annen informasjon i det at den også gir informasjon om 
nære familiemedlemmer sin risiko. Dette gjør håndteringen av informasjonen spesiell, og det kan være av 
betydning for familiemedlemmer å få del i kunnskap om bærerstatus. Vi ønsker å innhente kunnskap, slik 
at vi kan legge til rette for at kreftpasienter får et best mulig tilbud i forhold til gentesting og oppfølging i 
fremtiden.  
 
Hvem blir invitert til å delta i studien? 
Pasienter som er under behandling for brystkreft eller eggstokkreft ved sykehusene i Helse Vest vil bli 
invitert til å delta. 
 
Hva innebærer studien? 
Dersom du er villig til å delta i delstudie 1, vil det bli tatt en blodprøve av deg, og du vil bli bedt om å fylle 
ut et skjema med opplysninger om egen sykdom og forekomst av kreftsykdommer i familien din. 
Blodprøven og skjemaet med opplysninger vil bli sendt til Senter for medisinsk genetikk og 
molekylærmedisin, sammen med undertegnet samtykkeskjema. Der vil prøven bli analysert for de 
hyppigst forekommende genfeil i BRCA1- og BRCA2-genene i den norske befolkningen. Ca 90 % av alle 
som hadde påvist genfeil i BRCA1-genet eller BRCA2-genet per juli 2009 (i Norge) hadde en av disse 
genfeilene.  
Svaret vil foreligge etter 2-4 uker. Dersom svaret er normalt (det er ikke påvist noen genfeil), vil du få 
informasjon om dette gjennom et brev fra en av prosjektmedarbeiderne. Dersom det blir påvist en genfeil, 
vil du bli oppringt fra en av prosjektmedarbeiderne og få tilbud om en genetisk veiledningssamtale innen 2 
uker. Resultatet vil også bli formidlet til din behandlende lege uansett resultat. Hvis det fremkommer 
andre opplysninger som gir grunnlag for å mistenke at det foreligger arvelig kreft i din familie, vil du også 
få en telefon fra en av prosjektmedarbeiderne, selv om resultatet av gentesten er normalt, se nedenfor.  
 ved genetisk testing av kvinner med 
nyoppdaget bryst-  
tilbud om gentest, det andre rett etter tilbud om gentest og det siste vel 6 måneder etter tilbud gentest. Det 
vil ta ca 20 min å fylle ut spørreskjemaene.  
 
Påvist genfeil - betydning for deg 
Kvinner som har en genfeil i BRCA1- eller BRCA2-genet har økt risiko for å få brystkreft og 
eggstokkreft. For kvinner som allerede har gjennomgått brystkreft innebærer dette en økt risiko for å 
få kreft igjen, enten i samme bryst dersom det er gjort brystbevarende operasjon, eller i det andre 
brystet. Behandlingen av arvelig brystkreft kan således tenke seg å bli annerledes og mer omfattende 
enn ved en sporadisk form for brystkreft. Denne mer omfattende behandlingen vil ofte innebære 
fjerning av hele brystet hvor kreftsvulsten ble funnet. Det vil også diskuteres risikoreduserende tiltak 
med hensyn på det friske brystet, enten i form av regelmessige kontroller med MR/mammografi eller 
ved kirurgisk fjerning av kjertelvevet. Risikoreduserende fjerning av eggstokker vil vanligvis 
anbefales ved ca 40 års alder til de som har fått påvist genfeil.  
For kvinner som har eggstokkreft vil behandlingen av kreftsykdommen ikke bli annerledes dersom 
det skulle påvises en genfeil. Men siden genfeilen medfører en høy risiko for også å få brystkreft, vil 
man ofte diskutere risikoreduserende tiltak med hensyn på brystkreft, vanligvis i form av 
regelmessige kontroller med MR/mammografi.  
 
Påvist genfeil - betydning for din familie 
Dersom det blir påvist en genfeil hos deg, kan dette ha betydning for andre personer i din familie. 
Dette vil bli drøftet med deg under den genetiske veiledningssamtalen. Barn og søsken av en person 
med genfeil i BRCA1- eller BRCA2-genet, har 50 % risiko for å være bærer av den samme genfeilen. 
Slektninger som ønsker det vil få tilbud om genetisk veiledning og gentest. Friske kvinner som får 
påvist genfeil i BRCA1- eller BRCA2-genet vil ha tilbud om risikoreduserende tiltak som skissert 
ovenfor. Menn som får påvist genfeil i BRCA2-genet kan bli anbefalt kontroller pga økt risiko for 
prostatakreft.  
 
Normalt resultat av gentesten 
De fleste kvinner vil få beskjed om at gentesten er normal, det vil si at vi ikke har funnet noen av de kjente 
norske genfeilene i BRCA1 eller BRCA2 genet. Men det finnes også andre årsaker til arvelig brystkreft og 
arvelig eggstokkreft. Det kan derfor i enkelte tilfeller være aktuelt med utvidet genetisk utredning/testing 
og genetisk veiledning. Dette kan være på bakgrunn av opplysninger om andre krefttilfeller i familien, du 
selv har hatt kreft flere ganger, du selv var svært ung da du fikk kreft, spesielle karakteristika ved 
kreftsykdommen hos deg eller opplysninger om brystkreft hos menn.   
 
Mulige ulemper 
For de som får påvist en genfeil kan dette oppleves som en ekstra belastning i en fase hvor man er under 
behandling for en alvorlig kreftsykdom. I tillegg vil det å få informasjon om at ens familiemedlemmer, 
spesielt søstre og døtre, vil være i risiko for å ha samme genfeil, være tøft å forholde seg til. Nye 
valgsituasjoner med hensyn på risikoreduserende tiltak, f.eks fjerning av eggstokker ved 40 års alder, vil 
også innebære en tilleggsbelastning, både for pasienten og for evt slektninger med samme genfeil. 
Tidsbruken ved å fylle ut spørreskjemaene kan representere en ulempe. Det vil ta ca. 20 min å fylle ut 
spørreskjema 1 og noe mindre tid på spørreskjema 2 og 3. Det kan også tenke seg at enkelte spørsmål i 




Fordelen med å få vite om man har en genfeil i BRCA1- eller BRCA2-genet kan være at man med det får 
en forklaring på hvorfor man ble syk, og evt. hvorfor mange i familien har vært rammet av kreftsykdom. 
For noen kan muligheten for å gjøre risikoreduserende tiltak med hensyn på ny kreftsykdom også være en 
stor fordel. Tilsvarende vil risikoreduksjon og mulighet for tidlig diagnostikk for slektninger også kunne 
oppfattes som en fordel, siden det er svært alvorlig sykdom det er snakk om, og risikoreduksjon vil kunne 
forhindre kreftutvikling og dermed sykelighet og død. 
Fordelen med å delta i delstudie 2 er at du kan med din erfaringskunnskap være med å bidra til et bedret 
fremtidig helsetilbud for andre pasienter i din situasjon.  
 
Hva skjer med prøvene og informasjonen om deg?  
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Resultatet av BRCA-gentesten blir lagret i prøvedatabasen og pasientjournalen ved 
Senter for medisinsk genetikk og molekylærmedisin og i din journal ved sykehuset der du blir behandlet 
for kreftsykdommen. Etter at prøvene er analysert for de vanlig forekommende genfeil i BRCA-genene vil 
de bli overført til en forskningsbiobank, se kapittel B. Opplysningene som er registrert om deg, inkl 
spørreskjemaene som utgjør delstudie 2 vil i avidentifisert form bli lagret på Haukeland 
Universitetssykehus sin forskningsserver inntil alle resultatene er bearbeidet og publisert.  
 
Kapittel B - Personvern, biobank, økonomi og forsikring 
 
Personvern 
Opplysninger som registreres om deg er personalia og opplysninger du selv gir på spørreskjema. I tillegg 
til denne informasjonen vil vi innhente informasjon om aktuell diagnose (inkl nærmere klassifisering av 
denne) og tidligere sykdommer fra din sykejournal ved sykehuset der du blir behandlet for 
kreftsykdommen. Det kan også bli innhentet informasjon om deg fra Kreftregisteret.  
 
Resultat av BRCA-gentesten vil bli oppbevart og meddelt deg og din behandlende lege som skissert 
ovenfor. For utvidete genetiske studier med tanke på å kartlegge andre genetiske faktorer som kan ha 
sammenheng med kreftutvikling, vil opplysningene og prøvene bli behandlet uten navn og fødselsnummer 
eller andre direkte gjenkjennende opplysninger. Resultater av disse undersøkelsene vil ikke bli knyttet 
direkte til deg, og du vil følgelig heller ikke få noen informasjon om disse resultatene. 
 
En kode knytter deg til dine opplysninger og prøver gjennom en navneliste. Det er kun autorisert personell 
knyttet til prosjektet som har adgang til navnelisten og som kan finne tilbake til deg.  
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.  
 
Haukeland Universitetssjukehus ved administrerende direktør er databehandlingsansvarlig. 
 
Biobank 
Blodprøvene som blir tatt og informasjonen utledet av dette materialet vil bli lagret i en forskningsbiobank 
ved Regionalt kompetansesenter for arvelig kreft. Hvis du sier ja til å delta i studien, gir du også samtykke 
til at det biologiske materialet og analyseresultater inngår i biobanken. Leder av Regionalt 
kompetansesenter for arvelig kreft, Helse Vest, p.t. Hildegunn Høberg Vetti, er ansvarshavende for 
forskningsbiobanken. Biobanken planlegges å vare til 2027. Etter dette vil materiale og opplysninger bli 
destruert og slettet etter interne retningslinjer.  
 
Utlevering av materiale og opplysninger til andre 
Hvis du sier ja til å delta i studiens del 1b), gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger utleveres til våre samarbeidspartnere ved Radboud University Nijmegen Medical Centre i 
Nederland. 
 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver  
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om deg. 
Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du trekker 
deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre opplysningene 
allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner.  
 
Økonomi  
Begge delstudiene og biobanken er finansiert av Regionalt kompetansesenter for arvelig kreft.  
 
Forsikring 
Ved deltagelse i studien gjelder pasientskadeerstatningsloven. 
 
Informasjon om utfallet av studien 
Resultater fra studien vil bli publisert i internasjonale vitenskapelige tidsskrift. Informasjon om resultatene 


















Del 1:  HADS 
Del 2: ISEL 
Del 3: IES-15 
Del 4:  DCS 
Del 1 
Her kommer noen spørsmål om hvordan du føler deg. For hvert spørsmål setter du kryss for et 
av de fire svarene som best beskriver dine følelser den siste uken. Ikke tenk for lenge på svaret 
 de spontane svarene er best. 
 
1. Jeg føler meg nervøs og urolig 
 
3  Mesteparten av tiden 
2  Mye av tiden 
1  Fra tid til annen 
0  Ikke i det hele tatt 
     
2. Jeg gleder meg fortsatt over tingene slik jeg pleide før 
 
0  Avgjort like mye 
1  Ikke fullt så mye 
2  Bare lite grann 
3  Ikke i det hele tatt 
 
3. Jeg har en urofølelse som om noe forferdelig vil skje  
 
3  Ja, og noe svært ille 
2  Ja, ikke så veldig ille 
1  Litt, bekymrer meg lite 
0  Ikke i det hele tatt 
 
4. Jeg kan le og se det morsomme i situasjoner 
 
0  Like mye som før 
1  Ikke like mye nå som før 
2  Avgjort ikke som før 
3  Ikke i det hele tatt  
     
5. Jeg har hodet fullt av bekymringer 
 
3  Veldig ofte 
2  Ganske ofte 
1  Av og til  
0  En gang i blant        
 
6. Jeg er i godt humør 
 
3  Aldri 
2  Noen ganger 
1  Ganske ofte 
0  For det meste 
 
7. Jeg kan sitte i fred og ro og kjenne meg avslappet 
 
0  Ja, helt klart 
1  Vanligvis 
2  Ikke så ofte 
3  Ikke i det hele tatt 
 
 
Appendix 3. Psychosocial quesionnaires
8. Jeg føler meg som om alt går langsommere 
 
3  Nesten hele tiden 
2  Svært ofte 
1  Fra tid til annen 
0  Ikke i det hele tatt 
         
9. Jeg føler meg urolig som om jeg har sommerfugler i magen 
 
0  Ikke i det hele tatt 
1  Fra tid til annen 
2  Ganske ofte 
3  Svært ofte 
 
10. Jeg bryr meg ikke lenger om hvordan jeg ser ut 
 
3  Ja, jeg har sluttet å bry meg 
2  Ikke som jeg burde 
1  Kan hende ikke nok 
0  Bryr meg som før 
 
11. Jeg er rastløs, som om jeg stadig må være aktiv 
 
3  Uten tvil svært mye 
2  Ganske mye 
1  Ikke så veldig mye 
0  Ikke i det hele tatt 
 
12. Jeg ser med glede frem til hendelser og ting 
 
0  Like mye som før 
1  Heller mindre enn før 
2  Avgjort mindre enn før 
3  Nesten ikke i det hele tatt 
      
13. Jeg kan plutselig få en følelse av panikk 
 
3  Uten tvil svært ofte 
2  Ganske ofte 
1  Ikke så veldig ofte 
0  Ikke i det hele tatt 
 
14.  Jeg kan glede meg over gode bøker, radio og TV 
 
0  Ofte 
1  Fra tid til annen 
2  Ikke så ofte 









Dette spørreskjemaet består av en serie med spørsmål og påstander som beskriver mennesker 
på ulike måter. Hvert av disse spørsmålene kan passe på deg i større eller mindre grad. For 
hvert spørsmål skal du velge den ruten som passer best med din vurdering av deg selv og sette 
kryss. Det er ingen riktige eller gale svar  velg det alternativet som best beskriver hvordan du 
opplever deg selv på disse områdene i livet ditt.   
 
 
1. Jeg kjenner noen jeg kan snakke med ofte og som jeg føler meg helt trygg på å ta opp 
ethvert problem jeg måtte ha 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
2. De fleste vennene mine synes jeg er dyktig 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
3. Jeg blir sjelden invitert til å gjøre noe sammen med andre  
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
4. Jeg føler meg ikke sterkt involvert i noen andre personers liv 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
5. Hvis jeg bestemte meg for å gå på kino eller lignende, ville jeg lett finne noen å gå 
sammen med 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
6. Jeg kjenner noen som kunne hjelpe meg med gamle møbler, kjøkkenutstyr og 
lignende hvis jeg flyttet til en ny leilighet/hus og trengte det. 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
 
7. De fleste av vennene mine er mer tilfreds og lykkeligere med seg selv enn det jeg er 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
8. Jeg kjenner ingen der jeg bor som ville låne meg bilen sin hvis jeg trengte det 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
9. Jeg kjenner ingen der jeg bor som kunne hjelpe meg med å gjøre  problemene mine 
mer oversiktlig og forståelig. 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
10. De bånd jeg har til mine nære venner er svært viktig for meg. 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
11. Jeg kan kontakte noen som jeg liker å være sammen med når jeg måtte ønske det 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
12. Jeg kjenner noen som jeg snakker med ofte og som jeg ville føle meg ekstra trygg på 
å ta opp ethvert seksuelt problem jeg måtte ha 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
13. Jeg kjenner ingen der jeg bor som ville bruke flere timer på å hjelpe meg med en 
viktig oppgave 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 





14. Jeg har noen som jeg vil beskrive som en nær og fortrolig venn eller venninne  
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
15. Jeg tilhører en gruppe der jeg bor som møtes regelmessig eller som regelmessig gjør 
ting sammen 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
16. De fleste av vennene mine mener jeg har fortjent de gode tingene som har skjedd i 
livet mitt 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
17. Det er ingen der jeg bor som jeg ville føle meg helt trygg på å ta opp følelser om 
ensomhet og depresjon 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
18. De fleste som kjenner meg godt setter stor pris på meg 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
19. Jeg har ikke et nært og kjærlig forhold til noen 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
20. Jeg kjenner noen som ville lånt meg 2000 kr hvis jeg trengte det for min egen del 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 




21. Jeg er ikke medlem av noen sosiale grupper eller foreninger (slik som idrettslag, 
kirkeforeninger og lignende) 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
22. Jeg kjenner ingen der jeg bor som kunne lage mat eller handle inn hvis jeg var syk 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
23. Det finnes ingen der jeg bor som jeg føler meg helt trygg på å snakke med om 
helseproblemer 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
24. De fleste har flere nære venner enn jeg har 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
25. Jeg føler meg følelsesmessig nær andre 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
26. Hvis jeg trenger en venn/venninne til å hjelpe med å pusse opp, så har jeg noen der 
jeg bor som ville hjelpe meg 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
27. Jeg kjenner noen som jeg snakker med ofte og som jeg ville føle meg helt trygg på å 
snakke med om mitt sosiale liv 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 




28. De fleste vennene/venninnene mine er mer interessante enn jeg 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
29. Jeg vet ikke om mange mennesker som virkelig bryr seg om meg 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
30. Jeg har ingen venner/venninner der jeg bor, utenom min ektefelle/samboer, som ville 
trøste meg ved å vise omsorg 
 
1  Passer helt for meg 
2  Passer delvis for meg 
3  Passer delvis ikke for meg 
4  Passer slett ikke for meg 
 
 
Del 3  
Nedenfor finner du en liste over utsagn fra mennesker som opplever vanskelige hendelser. 
Vennligst les hvert utsagn og indiker hvor ofte disse kommentarene har vært riktige for deg i 
løpet av de siste syv dagene . Hvis du ikke har opplevd noen av disse reaksjonene i denne 
perioden, vennligst  
 
1. Jeg har hatt perioder med sterke følelser omkring det å ha fått en kreftsykdom 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
2. Ting jeg har sett og hørt minnet meg plutselig om det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
3. Tanker om det å ha kreft har trengt seg på også når jeg ikke har villet 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
4. Bilder av det å ha kreft har plutselig dukket opp i tankene mine  
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
5. Enhver påminnelse har vekket følelser knyttet til det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
6. Jeg har hatt vanskelig for å sove på grunn av tanker og bilder om det å ha fått en 
kreftsykdom 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
7. Jeg har vonde drømmer om det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
8. Jeg vet mange uforløste følelser om kreft er der, men jeg har skjøvet dem bort 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
9. Jeg har ikke tillatt meg å bli følelsesmessig berørt når jeg tenker på det å ha en 
kreftsykdom eller blir minnet på det 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
10. Jeg har ønsket å bli kvitt minner om det å ha en kreftsykdom 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
11. Jeg har forsøkt å la være å snakke om det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
12. Jeg har opplevd det uvirkelig, som om det å ha en kreftsykdom ikke var virkelig 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
13. Jeg har holdt meg unna ting eller situasjoner som kan minne meg om det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
14. Mine følelser om det å ha kreft er nærmest lammende 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 
5  Aldri 
 
15. Jeg har ikke tillatt meg selv å ha tanker om det å ha kreft 
 
0  I høy grad 
1  Ganske mye 
2  Middels 
3  Noe 
4  Litt 





Under kommer noen spørsmål knyttet til valget om å ta en gentest eller ikke og hvor godt 
forberedt du synes du er.  
 
A. Hvilket valgalternativ foretrekker du? Vennligst kryss av. 
 
  Gjennomføre gentest 
  Ikke gjennomføre gentest 
 
B. Tenk nå på det valget du er i ferd med å ta/nettopp har tatt, og les følgende kommentarer 
andre personer kan ha når de er i ferd med å ta valg om behandling etc. Marker hvor enig eller 
uenig du er ved å sette kryss i den ruten fra (meget enig) til (meget uenig), som passer best 
med det valget du er i ferd med å ta/nettopp har tatt. 
 
 
1. Jeg vet hvilke valgalternativ som er tilgjengelig for meg. 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
2. Jeg kjenner til fordeler med de ulike valgalternativene 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
3. Jeg kjenner til hvilke risikoer og ulemper de ulike valgalternativene har 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
4. Jeg har klart for meg hvilke fordeler som er viktigst for meg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
5. Jeg har klart for meg hvilke risikoer og ulemper som påvirker meg mest 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
6. Jeg har klart for meg hva som er viktigst for meg (fordeler eller risikoer/ulemper) 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
7. Jeg har tilstrekkelig støtte fra andre til å foreta valget 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
8. Jeg velger uten press fra andre 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
9. Jeg har nok innsikt til å foreta valget 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
10. Jeg har klart for meg hva som er det beste valgalternativet for meg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
11. Jeg er sikker på hva jeg skal velge 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
12. Jeg føler det er et enkelt valg å ta 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
13. Jeg føler jeg har foretatt et informert valg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
14. Mitt valg viser hva som er viktig for meg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
15. Jeg forventer at jeg vil holde fast ved mitt valg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
16. Jeg er tilfreds meg mitt valg 
 
0  Meget enig 
1  Enig 
2  Verken enig eller uenig 
3  Uenig 
4  Meget uenig 
 
Dersom du ønsker å gjennomføre gentest, vennligst gå til spørsmål C 
Dersom du ikke ønsker å gjennomføre gentest, vennligst gå til spørsmål D 
 
C.  
Dersom du har krysset av for at du ønsker å gjennomføre en gentest, kan du angi 






Dersom du har krysset av for at du ikke ønsker å gjennomføre en gentest, kan du angi 





Dersom du ikke ønsker gentest på det nåværende tidspunkt, tror du at du vil vurdere 
gentest ved en senere anledning? 
  Ja 
  Nei 
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